#  @andrewcaravello Andrew Caravello, DO Andrew Caravello, DO posts on X about $nwbo, $mrk, in the, cell the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::244291506/interactions)  - [--] Week [-------] +306% - [--] Month [-------] +293% - [--] Months [-------] -74% - [--] Year [---------] +1,115% ### Mentions: [--] [#](/creator/twitter::244291506/posts_active)  - [--] Week [--] +43% - [--] Month [---] +92% - [--] Months [---] +52% - [--] Year [---] +1,915% ### Followers: [-----] [#](/creator/twitter::244291506/followers)  - [--] Week [-----] +0.73% - [--] Month [-----] +2.90% - [--] Months [-----] +33% - [--] Year [-----] +219% ### CreatorRank: [-------] [#](/creator/twitter::244291506/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) 20.69% [finance](/list/finance) 9.66% [cryptocurrencies](/list/cryptocurrencies) 6.21% [currencies](/list/currencies) 2.76% [technology brands](/list/technology-brands) 2.07% [exchanges](/list/exchanges) 1.38% [countries](/list/countries) 1.38% [travel destinations](/list/travel-destinations) 0.69% [automotive brands](/list/automotive-brands) 0.69% **Social topic influence** [$nwbo](/topic/$nwbo) #1, [$mrk](/topic/$mrk) #37, [in the](/topic/in-the) 8.28%, [cell](/topic/cell) 6.9%, [the most](/topic/the-most) 5.52%, [hidden](/topic/hidden) 4.83%, [brain](/topic/brain) 4.83%, [$gme](/topic/$gme) #311, [gme](/topic/gme) #257, [platform](/topic/platform) 4.14% **Top accounts mentioned or mentioned by** [@grok](/creator/undefined) [@michaeljburry](/creator/undefined) [@theroaringkitty](/creator/undefined) [@wallstreetbets](/creator/undefined) [@thomasowenmcca1](/creator/undefined) [@drmakaryfda](/creator/undefined) [@kshaughnessy2](/creator/undefined) [@maveric92283613](/creator/undefined) [@cohenmilstein](/creator/undefined) [@mhragovuk](/creator/undefined) [@tosdd20](/creator/undefined) [@flatearthbarbie](/creator/undefined) [@aoevcbreakthru](/creator/undefined) [@ucla](/creator/undefined) [@berlinergy](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@atlnsider](/creator/undefined) [@ablidy](/creator/undefined) [@andrewecker829](/creator/undefined) [@michael48826289](/creator/undefined) **Top assets mentioned** [Merck & Co., Inc. (MRK)](/topic/$mrk) [GameStop, Corp. (GME)](/topic/$gme) [AstraZeneca PLC (AZN)](/topic/$azn) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Amgen, Inc. (AMGN)](/topic/$amgn) [Thermo Fisher Scientific Inc. (TMO)](/topic/$tmo) [Pfizer, Inc. (PFE)](/topic/$pfe) [AMC Entertainment Holdings, Inc. (AMC)](/topic/$amc) [ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) [Polymesh (POLYX)](/topic/polymesh) ### Top Social Posts Top posts by engagements in the last [--] hours "❄ The Hidden Architecture Part [--] of [--] When the Machine Switches On The $TMO Thermal and Industrial Gates of $MRK $EIKN $AMGN #Zeon and the $NWBO #DCVax Immune Operating System 🏭 [--] The Precision Fit For Advent and Northwest Biotherapeutics Zeons role has always felt inevitable. Flaskworks greatest mechanical obstacle dendritic cells adhering to vessel walls like barnacles was the very problem Zeon had already solved through material science. Zeons proprietary polymers ZEONEX and ZEONOR are hydrophilic protein-repellent chemically stable and cryo-safe to minus [---] degrees Celsius. These films" [X Link](https://x.com/andrewcaravello/status/1984303713150706153) 2025-10-31T16:57Z [----] followers, [----] engagements "🔥 The Biggest Short: How $NWBO #DCVax Exposes a Market Rigged Like [----] @MichaelJBurry__ $GME vs #NWBO @TheRoaringKitty From meme-stock mayhem to a cancer therapys fight for fair value How a @wallstreetbets short squeeze became a moviewhile a cancer breakthroughs struggle against market manipulation became a federal court case. 🎬 Introduction From Subprime to Spoofing In [----] Adam McKays The Big Short took audiences inside the surreal world of the U.S. housing bubble. Michael Lewiss book and McKays film showed how a few contrarian investors like Michael Burry pieced together what the world" [X Link](https://x.com/anyuser/status/1958775352995848290) 2025-08-22T06:16Z [----] followers, 21.3K engagements "🧱 Tokenizing Trust: Why $NWBO Should Build On Polymesh for Investor Protection Market Integrity IP Security and Long-Term Capital Access TLDR Tokenization is no longer a fringe idea or a crypto experiment. It is becoming a mainstream modernization of traditional market infrastructure but only when executed within the full regulatory framework that governs U S securities. SIFMA the primary policy voice of broker-dealers investment banks custodians and clearing firms has stated openly that tokenized markets must operate with the same investor protections surveillance transparency and lifecycle" [X Link](https://x.com/andrewcaravello/status/1998907262094442644) 2025-12-11T00:06Z [----] followers, [----] engagements "🧨 Short Circuit in Penny Stock Land: How $NWBO Built a Quiet Exit Ramp From the OTC Trap Before anyone pins this story to a single day the boundary gets drawn once and cleanly. What is known is boring and checkable. NWBO has an existing London Stock Exchange line under ticker 0K95 with ISIN US66737P6007 and the LSEs instrument page shows an issue date of [--] January [----]. On [--] January [----] the UKs new public offers and admissions regime takes effect and the FCAs final rules in PS25/9 raise the further issuance prospectus trigger for transferable securities already admitted to trading from" [X Link](https://x.com/andrewcaravello/status/2012632215948083277) 2026-01-17T21:04Z [----] followers, 20.3K engagements "🧬#PanCAN #PanCANPurpleStride $AZN $AIM $MRK NorthWest Biotherapeutics Inc ( $NWBO ):A Dendritic CellCentered Immune Circuit for Cold Solid Tumors Rebuilding Immunotherapy as a Manufacturing Pipeline for Pancreatic Ductal Adenocarcinoma via @Investors_Hub https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177226439 https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177226439 https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177226439 https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177226439" [X Link](https://x.com/andrewcaravello/status/2016216278290067628) 2026-01-27T18:26Z [----] followers, [----] engagements "@grok Please provide an exhaustive list of biopharma companies that stand to benefit from combining with $NWBO given its role as the AWS of immunotherapy" [X Link](https://x.com/andrewcaravello/status/2017260166735917363) 2026-01-30T15:34Z [----] followers, [---] engagements "Winterfell. ❄ $MRK WP50: [------] sq ft GMP-certified lyophilizer-integrated cryo-staged. Built for modular immune kitsnot bulk vaccine. Complete since mid-2025. Yet: zero product named zero go-live date zero announcement. Idle capital of $200500M. This is not normal Merck. The silence is the signal. $NWBO #DCVax 🧭 The Scout the Silence and the System How $MRK Built What $BMY Walked Past and What $NWBO Had Already Finished In late [----] something unusual happened. Dr. Kevin Duffy Mercks Research Scientific Director on the Keytruda program quietly stepped away from one of the most" [X Link](https://x.com/andrewcaravello/status/2018522896084111426) 2026-02-03T03:12Z [----] followers, [---] engagements "🕋The $NWBO Operating System How adoptive T-cell therapy evolved from brute-force expansion to durable immune control why cohorts mattered and why #ACT #DCVax $MRK $EIKN systemic #EIK1001 TLR78 $AZN #Imfinzi PD-L1 blockade #RevImmune #CYT107 IL-7 and #EDEN-class automation belong together Executive Summary Adoptive T-cell therapy (ACT) began as a brute-force strategy to deliver a massive wave of tumor-reactive T cells. It produced real tumor regressions but durability was inconsistent because transferred cells often failed to persist traffic and remain functional long enough to prevent" [X Link](https://x.com/andrewcaravello/status/2018913953779196262) 2026-02-04T05:06Z [----] followers, [----] engagements "@grok In Game of Thrones terms why would $MRK prioritize systemic TLR7/8 EIK1001 to ignite immunity before PD-1/PD-L1 or adoptive T-cell therapy (ATC)if the real problem in solid tumors is durability not just initial response How does this logic pair with $NWBO #DCVax as the system that teaches antigen breadth while ❄ Winterfell represents the infrastructure needed to sustain and defend those gains over time And does $EIKN IPO signal more than raising moneydoes it mark Mercks intent to field a reusable ignition layer designed to make immune responses hold the line across checkpoints and ATC" [X Link](https://x.com/andrewcaravello/status/2019002926157512830) 2026-02-04T10:59Z [----] followers, [---] engagements "@bun_macs @grok $NWBO #DCVax $MRK $EIKN $AZN @andrewcaravello In Game of Thrones terms solid tumors are like the White Walkersrelentless adaptive threats that initial strikes (PD-1/PD-L1 or ATC) can wound but not eradicate without lasting defenses. Merck prioritizes EIK1001 as wildfire ignition: it awakens the realm's dendritic sentinels @andrewcaravello In Game of Thrones terms solid tumors are like the White Walkersrelentless adaptive threats that initial strikes (PD-1/PD-L1 or ATC) can wound but not eradicate without lasting defenses. Merck prioritizes EIK1001 as wildfire ignition: it" [X Link](https://x.com/andrewcaravello/status/2019003719702954412) 2026-02-04T11:02Z [----] followers, [---] engagements "$NWBO #DCVax The future of cancer care starts now with the National Cancer Plan. Here's how we're transforming diagnosis treatment and support for patients 👇 https://t.co/WFabOkzoWv https://t.co/31BXmQ9zvj The future of cancer care starts now with the National Cancer Plan. Here's how we're transforming diagnosis treatment and support for patients 👇 https://t.co/WFabOkzoWv https://t.co/31BXmQ9zvj" [X Link](https://x.com/andrewcaravello/status/2019019424272134468) 2026-02-04T12:05Z [----] followers, [----] engagements "📜 $NWBO #DCVax-L and the UK National Cancer Plan [----] for #WorldCancerDay #GBM Strengthening the Case for Approval and Adoption Through the Plans Survival Mandate Lens Introduction and Executive Summary The [----] National Cancer Plan is built around survival as the primary measure of NHS performance. The Technical Annex explicitly states that survival is used because it is more useful for understanding the performance of the NHS in diagnosing and treating cancer and because mortality statistics are lagged and less sensitive to improvements in care once cancer develops. The Plan sets a" [X Link](https://x.com/andrewcaravello/status/2019041028297146462) 2026-02-04T13:31Z [----] followers, [----] engagements "$NWBO #DCVax #WorldCancerDay #GBM 👇🏻👇🏻👇🏻 @andrewcaravello The UK's [----] National Cancer Plan released on World Cancer Day paves the way for DCVax approval and NHS access by: - Setting 75% 5-year survival as the core metric to drive outcomes in laggard cancers like GBM. - Prioritizing brain tumors with focused research and @andrewcaravello The UK's [----] National Cancer Plan released on World Cancer Day paves the way for DCVax approval and NHS access by: - Setting 75% 5-year survival as the core metric to drive outcomes in laggard cancers like GBM. - Prioritizing brain tumors with focused" [X Link](https://x.com/andrewcaravello/status/2019044552125108426) 2026-02-04T13:45Z [----] followers, [---] engagements "$NWBO #DCVax #WorldCancerDay @MHRAgovuk The difference between now and later is measured in lives. @andrewcaravello @MHRAgovuk [--]. MHRA Approval: - Provision: Accelerated Review for Rare Cancers (Annex 2.1) - Allows fast-track for GBM therapies; cuts review time 50%. - Matters for DCVax: Enables quick approval for personalized vaccine. [--]. NICE Appraisal: - Provision: Severity Modifier for Laggard Cancers @andrewcaravello @MHRAgovuk [--]. MHRA Approval: - Provision: Accelerated Review for Rare Cancers (Annex 2.1) - Allows fast-track for GBM therapies; cuts review time 50%. - Matters for DCVax:" [X Link](https://x.com/andrewcaravello/status/2019047276908626431) 2026-02-04T13:55Z [----] followers, [----] engagements "$NWBO #DCVax #GBM #WorldCancerDay Just 12% of brain cancer patients live [--] yrs post diagnosis- light years from the 75% target in the NHS Cancer plan Weve seen no new treatments in [--] yrs for the cancer that kills more kids & adults [--] than any other Lets hope this rising tide lifts all boats #WorldCancerDay https://t.co/F666J64eRL Just 12% of brain cancer patients live [--] yrs post diagnosis- light years from the 75% target in the NHS Cancer plan Weve seen no new treatments in [--] yrs for the cancer that kills more kids & adults [--] than any other Lets hope this rising tide lifts all boats" [X Link](https://x.com/andrewcaravello/status/2019051582780813559) 2026-02-04T14:13Z [----] followers, [----] engagements "🧭 The Tail They Learned to Trust Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK $PFE $AMGN $REGN and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained inside the same KEYTRUDA franchise on complementary lanes and exposed to the same constraint that still governs outcomes across tumors. PD-1 blockade became the defining franchise in cancer medicine and both learned its boundary from different sides of the machine. Checkpoint blockade can amplify an immune response that" [X Link](https://x.com/andrewcaravello/status/2019613805165089230) 2026-02-06T03:27Z [----] followers, [---] engagements "💉WHY DENDRITIC CELL VACCINES ARE NOT REALLY VACCINES There is a word we keep using because it is familiar comforting and politically convenient. Vaccine. It is a word that suggests a simple story. A small dose. A clean lesson. A memory formed. A future prevented. In cancer that story breaks down. Not because the concept of immune teaching is wrong but because the classroom has been sabotaged. So when modern oncology calls dendritic cell therapy a vaccine it is using a label that obscures the most important fact in the entire enterprise. A classic vaccine is information. A dendritic cell" [X Link](https://x.com/andrewcaravello/status/2019728684542755050) 2026-02-06T11:03Z [----] followers, 13.5K engagements "@grok explain why most cancer immunotherapy modalities require humans to pre-decide which tumor epitopes matter while $NWBO #DCVax delegates that decision to immune biology itself. Start by briefly defining what an epitope is and why choosing the right epitope is hard in heterogeneous solid tumors (clonal vs subclonal expression antigen loss immune editing and tumor evolution). Then compare one by one the following modalities: peptide cancer vaccines mRNA cancer vaccines neoantigen vaccines CAR-T / TCR-engineered T cells antibodydrug conjugates and bispecifics For each modality explain" [X Link](https://x.com/andrewcaravello/status/2019764831033659727) 2026-02-06T13:27Z [----] followers, [---] engagements "Jessina thank you for responding and I agree with you. If the brakes are still engaged a push of gas mainly buys a transient spike. Counts can rise and activation can look impressive but long term control is unlikely because the constraints that shut immune function down are still there. Thats exactly why Im uneasy with the way cytokines are sometimes talked about as if theyre the cure. Cytokines can amplify NK cells and T cells and that can be useful but amplifying execution downstream is not the same as building durable surveillance upstream. If the immune system was never properly" [X Link](https://x.com/andrewcaravello/status/2019877050157342938) 2026-02-06T20:53Z [----] followers, [--] engagements "❄PROJECT WINTERFELL $MRK Silent Manufacturing Network and the $NWBO #DCVax Immune Kit Platform PREFACE This is not a story about one building. It is a story about an ecosystem being assembled to function as a unit. Along a short corridor in Montgomery County Pennsylvania West Point North Wales and Upper Gwynedd sit as physically adjacent nodes. Close enough to behave like one campus organism separate enough to be disclosed and described as distinct pieces. West Point is the production heart. North Wales and Upper Gwynedd are the quality spine. The cold chain nodes are the circulation system." [X Link](https://x.com/andrewcaravello/status/2020092380855013390) 2026-02-07T11:08Z [----] followers, [----] engagements "@grok @Tosdd20 Explain why it makes financial and logistical sense as a partnership" [X Link](https://x.com/andrewcaravello/status/2020191154990694878) 2026-02-07T17:41Z [----] followers, [---] engagements "🧠 DCVax Is the Base Layer: Why the GBM Immunity Cycle Is Not Broken but Rerouted by Failed Combination Architecture $NWBO #DCVax (ATL-DC) #Hiltonol poly-ICLC $MRK #Keytruda pembrolizumab $BMY #Opdivo nivolumab $BMY #Yervoy ipilimumab $BMY #Opdualag nivolumab + relatlimab $AZN #Imfinzi durvalumab $AZN #Imjudo tremelimumab $RHHBY #Tecentriq atezolizumab $RHHBY #Avastin bevacizumab $RHHBY #Actemra tocilizumab $REGN #Kevzara sarilumab $SNY #Mozobil plerixafor $BLRX #Aphexda motixafortide $DSNKY #Turalio pexidartinib $PFE #Celebrex celecoxib $GSK #Selzentry maraviroc $EIKN EIK1001 $LLY #Cialis" [X Link](https://x.com/andrewcaravello/status/2020218733579366905) 2026-02-07T19:30Z [----] followers, [----] engagements "🏰❄ $MRK Winterfell Booster-Class Architecture Why Combinatorial $NWBO #DCVax Booster Classes Require #Lyophilization and Make Personalization Possible at Scale The system requires lyophilization for one operational reason: it is not built around a single adjuvant. It is built around multiple booster classes used in combination. The approach uses a tunable stack of immune stimulatory agents applied to dendritic cells before injection including TLR agonists antiviral pathway activators biological response modifiers and danger signals. Each class functions as a modular component that can be" [X Link](https://x.com/andrewcaravello/status/2020360291075178661) 2026-02-08T04:53Z [----] followers, [----] engagements "@DrMLernerMDPhD Hmmm. #DCVax nasal spray. Not a bad idea. Except its already intradermal so not too shabby for a treatment that can already defeat #Glioblastoma" [X Link](https://x.com/andrewcaravello/status/2020696834663235919) 2026-02-09T03:10Z [----] followers, [--] engagements "http://x.com/i/article/2020774294851121152 http://x.com/i/article/2020774294851121152" [X Link](https://x.com/andrewcaravello/status/2020783687223111976) 2026-02-09T08:55Z [----] followers, 124.4K engagements "@grok Execution is the state that cant stay stable. Derailment/tolerance is the default attractor. First broken governor is the myeloid gate; CD4DC licensing is the permission switch; timing decides whether checkpoint blockade stabilizes execution or accelerates myeloid capture" [X Link](https://x.com/andrewcaravello/status/2020810712080060540) 2026-02-09T10:43Z [----] followers, [--] engagements "Spatial data doesnt add curiosityit adds ground truth. When scRNA/TCR trajectories are overlaid with spatial transcriptomics the system can directly observe whether execution is territorially consolidating (cDC1T cell colocalization CXCL9/10 gradients productive immune synapses) or whether myeloid capture has already occurred (macrophage-dominant antigen presentation IL-6/IL-8/IL-10/TGF- loops exclusionary CXCL12 niches). That combination turns timing into a measurable control variable not a retrospective guess. It allows durable response to be identified weeks to months after" [X Link](https://x.com/andrewcaravello/status/2020813787834581421) 2026-02-09T10:55Z [----] followers, [--] engagements "@grok The core innovation is not AI-driven state detection but NWBOs ability to predefine and lock immune state via digital GMP; once biology is governed upstream analytics become routine bookkeeping rather than discovery" [X Link](https://x.com/andrewcaravello/status/2020816860644610552) 2026-02-09T11:07Z [----] followers, [---] engagements "This model shifts regulation from outcome-waiting to process-validation. By enforcing immune instruction upstream through digital GMP at #AdventBioServicesdefined #DCVax dendritic-cell state cytokine profile timing and release criteria $NWBO turns a personalized therapy into a reproducible auditable manufacturing process. Regulators can evaluate control of the governing variables rather than waiting years for downstream clinical endpoints alone. In practice this shortens timelines because durability is no longer inferred retrospectively; it is engineered prospectively. Approval becomes about" [X Link](https://x.com/andrewcaravello/status/2020818894949072900) 2026-02-09T11:15Z [----] followers, [---] engagements "@grok You can do better than that list them all" [X Link](https://x.com/andrewcaravello/status/2020830192978235620) 2026-02-09T12:00Z [----] followers, [--] engagements "@grok Keep going" [X Link](https://x.com/andrewcaravello/status/2020830681904136349) 2026-02-09T12:02Z [----] followers, [--] engagements "#DCVax-Ls potential MHRA approval would almost certainly be tumour-specific at first anchored in #glioblastoma given the Phase [--] dataset orphan drug designation and PIM status. That is how UK approvals are formally labelled. However approval would do more than validate a single #GBM indication. It would validate the autologous dendritic-cell immune-instruction method itself supported not only by randomized trial data but also by substantial real-world experience. To date hundreds of patients have received DCVax-class therapy under compassionate use expanded access and non-randomized clinical" [X Link](https://x.com/andrewcaravello/status/2020882298355204349) 2026-02-09T15:27Z [----] followers, [---] engagements "@grok $NWBO #DCVax Approval + existing RWE doesnt just speed bridging studies it changes what regulators already accept as established. Thats the difference between extending a method and launching a new drug each time" [X Link](https://x.com/andrewcaravello/status/2020883359266738219) 2026-02-09T15:31Z [----] followers, [---] engagements "Based on MHRAs published guidance on using real world data to support regulatory decisions what parts of $NWBO #DCVaxs existing real world evidence can legitimately carry forward after a GBM label approval: safety manufacturing reproducibility release consistency and durability signals And under the same MHRA standards would #murcidencel-associated datasets count as supportive method-level evidence if NWBO can demonstrate manufacturing comparability and aligned critical quality attributes under GMP control strategy expectations Finally how does the National Cancer Plans CVLP/VIP + Cancer" [X Link](https://x.com/andrewcaravello/status/2020884405644919255) 2026-02-09T15:36Z [----] followers, [---] engagements "@grok The trick is that you do not standardize all the data. You standardize the immune state. $NWBO Digital GMP locks the cassette (repeatable immune mode ) at manufacture and regulators verify the cassette not raw omics" [X Link](https://x.com/andrewcaravello/status/2020959386999587326) 2026-02-09T20:34Z [----] followers, [---] engagements "@grok Zero-knowledge works here because the biology is already discrete. Digital GMP locks the immune state; blockchain proves custody; ZK proofs confirm compliance without exposing data. The breakthrough isnt AIits state control" [X Link](https://x.com/andrewcaravello/status/2020963610407862656) 2026-02-09T20:50Z [----] followers, [--] engagements "$NWBO #DCVax basket trials accelerate this by keeping the approval question mechanism based while still producing indication specific evidence where it matters. A basket trial tests one therapy built on one plausible mechanism across multiple tumor types at once using the same manufacturing state the same release signature and the same prespecified definition of clinical benefit. Each tumor type remains its own cohort with its own endpoints and safety readout but the program moves faster because enrollment monitoring and decision rules are shared instead of rebuilt from scratch each time." [X Link](https://x.com/andrewcaravello/status/2020974447310639522) 2026-02-09T21:33Z [----] followers, [---] engagements "Real world evidence is where the cassette model becomes a feedback loop instead of a one time bet. Once a patient specific whole tumor lysate #DCVAax product is manufactured under $NWBO #AdventBioServices digital GMP every batch already has a defined starting condition. The payload is the patients own lysate and the release phenotype is the cassette. Execution derailment or tolerogenic. That means post approval data can be interpreted as state outcomes not as noise. Real world evidence can then do three concrete jobs. [--]. Detect early whether execution is holding or collapsing If patients show" [X Link](https://x.com/andrewcaravello/status/2020975781904539871) 2026-02-09T21:39Z [----] followers, [---] engagements "Execution quality determines surveillance quality. Low-antigen surveillance is governed by Boolean cytotoxic logic established during execution not by continuous cytokine readouts. If execution installs a properly licensed Type [--] program memory T cells retain DNAM-1conditioned readiness and can respond rapidly when antigen reappears even as overall immune tone returns to homeostasis. Wearable cytokine sensors may add supportive context but they are secondary. Cytokine levels will naturally normalize once tumor burden is cleared and do not reliably indicate surveillance competence. The" [X Link](https://x.com/andrewcaravello/status/2021048442278076909) 2026-02-10T02:27Z [----] followers, [--] engagements "It shifts pricing away from units delivered and toward durability delivered because #EDEN-class Digital GMP makes durability reproducible rather than accidental. When federated learning shows that the same EDEN-locked execution cassette produces consistent recurrence-free survival across geographies #DCVax no longer has to be priced as an artisanal one-off cell product. It can be priced as a durable immune control platform whose performance is enforced at manufacture. That enables three concrete changes: First outcomes-based pricing becomes defensible. Because EDEN enforces a fixed execution" [X Link](https://x.com/andrewcaravello/status/2021055568253751415) 2026-02-10T02:56Z [----] followers, [--] engagements "@grok EDEN locks the immune state. Blockchain proves it wasnt altered. Payers then price durabilityrecurrence-free survivalnot tumor labels. Thats how value-based contracts finally work for personalized therapies" [X Link](https://x.com/andrewcaravello/status/2021056172040806770) 2026-02-10T02:58Z [----] followers, [--] engagements "@grok What would Dr. Andrew Taylor Still say about this" [X Link](https://x.com/andrewcaravello/status/2021196488572010523) 2026-02-10T12:16Z [----] followers, [--] engagements "@grok What would Hippocrates say about this" [X Link](https://x.com/andrewcaravello/status/2021199903322669233) 2026-02-10T12:29Z [----] followers, [--] engagements "@grok explain how durable survival could theoretically approach functional cure rates by optimizing the cytokine circuit" [X Link](https://x.com/andrewcaravello/status/2021422578720702677) 2026-02-11T03:14Z [----] followers, [--] engagements "@grok explain how durable survival could theoretically approach functional cure rates by optimizing the cytokine circuit mentioned in the post not as a single drug effect but as a coordinated immune reprogramming strategy" [X Link](https://x.com/andrewcaravello/status/2021424324566294603) 2026-02-11T03:21Z [----] followers, [--] engagements "What youre saying makes sense. It feels like the system is trying to ensure the incumbents still get a lane so the mRNA vaccine narrative can function as a politically tidy on-ramp that ultimately makes a dendritic-cell platform like #DCVax easier to approve without looking like a sudden regulatory pivot. https://twitter.com/i/web/status/2021658818250174959 https://twitter.com/i/web/status/2021658818250174959" [X Link](https://x.com/andrewcaravello/status/2021658818250174959) 2026-02-11T18:53Z [----] followers, [--] engagements "@grok @FlatEarthBarbie @ThomasOwenMcCa1 @AOEvcBreakthru @kshaughnessy2 @UCLA Now interpret this survival curve" [X Link](https://x.com/andrewcaravello/status/2022107166401016315) 2026-02-13T00:34Z [----] followers, [--] engagements "@grok @FlatEarthBarbie @ThomasOwenMcCa1 @AOEvcBreakthru @kshaughnessy2 @UCLA Look again. Its well over [--] percent" [X Link](https://x.com/andrewcaravello/status/2022108587691274507) 2026-02-13T00:40Z [----] followers, [--] engagements "$NWBO #DCVax $GME $MMTLP @MichaelJBurry__" [X Link](https://x.com/andrewcaravello/status/2022278443799359968) 2026-02-13T11:55Z [----] followers, [---] engagements "@grok @Berlinergy So what would that mean for glioblastoma patients Have you seen anything like this before" [X Link](https://x.com/andrewcaravello/status/2022377932581130457) 2026-02-13T18:30Z [----] followers, [--] engagements "@grok Ok which state is failing to stay stable over time: execution or tolerance/derailment And whats the first broken governor: CD4DC licensing myeloid gate or timing Please explain your answer" [X Link](https://x.com/andrewcaravello/status/2020809809319063957) 2026-02-09T10:39Z [----] followers, [--] engagements "$NWBO #DCVax $GME $AMC $MMTLP @MichaelJBurry__ @TheRoaringKitty 🔥🔒 The Inverse Lock-Up: How $NWBO #DCVax Approval Unleashes a Scarcity Shock #BiggestShort #InverseLockUp $GME $AMC made headlines. #NWBO was kept in silence. One was a meme-stock spectacle. The other is the biggest short hiding in plain sight. @wallstreetbets @MichaelJBurry__ 🔥🔒 The Inverse Lock-Up: How $NWBO #DCVax Approval Unleashes a Scarcity Shock #BiggestShort #InverseLockUp $GME $AMC made headlines. #NWBO was kept in silence. One was a meme-stock spectacle. The other is the biggest short hiding in plain sight." [X Link](https://x.com/andrewcaravello/status/2022279771296506195) 2026-02-13T12:00Z [----] followers, [----] engagements "What randomized evidence proves that correcting low ALC with IL-15 improves survival rather than simply changing a biomarker And mechanistically if the goal is broad T-cell reconstitution in true lymphopenia wouldnt IL-7given its role in nave and CD4 T-cell homeostasisbe more physiologically aligned than IL-15 which primarily expands NK and memory CD8 populations" [X Link](https://x.com/andrewcaravello/status/2022891883345629405) 2026-02-15T04:33Z [----] followers, [--] engagements "$NWBO $MRK A Theory Worth Considering: What If Merck and NWBO Joined Forces Post-Approval This isnt a prediction. Its not a leak. Its not investment advice. Its a theory rooted in logic market timing and the accelerating shift in oncology. With NWBOs DCVax-L potentially nearing approval by the UKs MHRA and Mercks stock trading at a relative low the conditions are emerging for a transformative alignment not a typical buyout but a merger of mutual need and global opportunity. One has the platform. The other has the infrastructure. Together they could build something neither could do alone." [X Link](https://x.com/andrewcaravello/status/1925935568208171445) 2025-05-23T15:23Z [----] followers, 12.7K engagements "🔥🔒 The Inverse Lock-Up: How $NWBO #DCVax Approval Unleashes a Scarcity Shock #BiggestShort #InverseLockUp $GME $AMC made headlines. #NWBO was kept in silence. One was a meme-stock spectacle. The other is the biggest short hiding in plain sight. @wallstreetbets @MichaelJBurry__ GameStop was loud a visible squeeze that turned into cinema. NWBO is quiet a suppressed float where approval collides with science. GameStop ended as cinema. NWBO begins as precedent. 🌍 Science and Silence Northwest Biotherapeutics is not just another biotech ticker. Its dendritic cell vaccine DCVax-L has done what" [X Link](https://x.com/andrewcaravello/status/1959498521431695465) 2025-08-24T06:10Z [----] followers, [----] engagements "🎼 The Symphony of the Immune Orchestra $NWBO #DCVax 🌅 Overture: The Theme Appears This is the story of how a scattered field of experiments became a coordinated platform and how one company quietly assembled the rights the factories and the leadership to bring it into the world. It begins as a whisper in the body. Blood is drawn white cells are separated and among them lie dendritic cells the quiet conductors of the immune system. They hold the capacity to take in the whole score of a tumor to present it back to T cells as a melody of recognition and to awaken the defense that was always" [X Link](https://x.com/andrewcaravello/status/1962207213780713549) 2025-08-31T17:33Z [----] followers, 50.5K engagements "@StevenBremMD Dr. Brem your perspective means a great deal. To see someone of your experience speak about the journey of $NWBO and DCVax with such clarity is both grounding and inspiring 🙏🏻" [X Link](https://x.com/andrewcaravello/status/1962269231677861947) 2025-08-31T21:40Z [----] followers, [----] engagements "🧬 $NWBO Q3 filing reveals a major operational #DCVax milestone: the company has chosen its U.S. GMP manufacturing site after evaluating two qualified facilities and has already entered contract negotiations and begun staffing the build-out. This is the quiet concrete work that marks a company preparing to operate. 🧬🔥 THE QUIET INFLECTION: How $NWBO Q3 [----] Filing Reveals a Company Moving From Development to Deployment A Global Forensic Deep-Read for Investors TLDR Northwest Biotherapeutics Q3 [----] Form 10-Q shows a company crossing a structural threshold. Without stating it outright 🧬🔥" [X Link](https://x.com/andrewcaravello/status/1989476355403133060) 2025-11-14T23:31Z [----] followers, [----] engagements "@grok Explain mechanistically why #RevImmune IL-7 (CYT107) is more reliable for true lymphopenia and #ALC recovery than $IBRX #Anktiva (IL-15 superagonist). Cover: IL-7 signals via IL-7R (CD127) to drive homeostatic survival and expansion of nave and central memory CD4 and CD8 rebuilding broad T cell mass and repertoire diversity. Contrast: IL-15 preferentially expands NK cells and CD8 effector memory through trans-presentation amplifying cytotoxic compartments without restoring depleted CD4 help or the nave pool. Then explain why Anktivas numbers can mislead: ALC is a blunt CBC count so it" [X Link](https://x.com/andrewcaravello/status/2019803830855070202) 2026-02-06T16:02Z [----] followers, [---] engagements "Shift gears from cancer execution to immune tolerance. Assume the core capability is deterministic programming of tolerogenic dendritic cells (tolDCs) that can reliably induce and maintain antigen-specific Treg dominance. [--]. What diseases or clinical stateschronic and acuteare fundamentally failures of immune tolerance where restoring it (not suppressing immunity globally) is the goal [--]. For each briefly note what tolerance must be restored (autoantigen alloantigen tissue-specific bystander). [--]. Then name types of companies (and examples) that would logically partner around such a tolDC" [X Link](https://x.com/andrewcaravello/status/2020837383818649883) 2026-02-09T12:29Z [----] followers, [--] engagements "The Force is strong with #DCVax @andrewcaravello Restore homeostasis you must. Immune force strong and balanced DCVax awakens. Starter teachers prime endogenous ones sustain. Escape antigen cannot when Type-1 logic flows. Equilibrium the ultimate path is. @andrewcaravello Restore homeostasis you must. Immune force strong and balanced DCVax awakens. Starter teachers prime endogenous ones sustain. Escape antigen cannot when Type-1 logic flows. Equilibrium the ultimate path is" [X Link](https://x.com/andrewcaravello/status/2021201452044255595) 2026-02-10T12:35Z [----] followers, [---] engagements "🧠 $NWBO #DCVax and the #Treg Blueprint: Why Durability Is a State Not a Schedule Wardell Boardman and Levings (Nat Rev Drug Discov 2025) make a clean point: regulatory T cells are not anti-inflammatory vibes. They are the immune systems control layer. They enforce tolerance by restraining APC co-stimulation reshaping the cytokine and metabolite field (IL-10 TGF CD39/CD73adenosine) and establishing a durable regulatory balance. They also emphasize how this must be measured in humans: specificity and stability not slogans (AIM assays functional suppression FOXP3 stability markers TSDR" [X Link](https://x.com/andrewcaravello/status/2021619697397961168) 2026-02-11T16:17Z [----] followers, [----] engagements "James Van Der Beeks story does not begin as a tragedy. It begins as a life that looks from the outside like it has already survived the hard part. Fame. Work. A wife. Six children. A public face that millions recognize on sight. Then colorectal cancer arrives. And the rules change. He dies at [--]. He leaves behind Kimberly and their six children. Six children is not a statistic. It is six separate mornings that still need to happen. Six lunches packed. Six backpacks by the door. Six bedtimes where a parent is expected to sound calm even when fear is loud. Cancer does not simply attack tissue." [X Link](https://x.com/andrewcaravello/status/2021968294060679276) 2026-02-12T15:23Z [----] followers, [----] engagements "🧠 Conversion Control in #Glioblastoma The CD4Dendritic Cell Interface as the Integrative Control Node of Durable Cancer Immunity and the Operationalization of the Teacher Layer Through the $NWBO #DCVax Ecosystem Executive summary Glioblastoma is frequently described as immune cold but the most actionable pattern across modern evidence is different: the immune system can be clearly activated and still lose. The dominant reason is conversion. Glioblastoma converts a real immune response into a different state that looks inflammatory but behaves non-curative. This review advances a Conversion" [X Link](https://x.com/andrewcaravello/status/2022006796601184412) 2026-02-12T17:56Z [----] followers, [---] engagements "🧬 Why the New Nature #mRNA Study Quietly Proves the Superiority of $NWBO #DCVax And Why mRNA Cancer Vaccines Cannot Match Dendritic-Cell Immunotherapy. and why the #FDA is correct. https://x.com/andrewcaravello/status/1999164784420299058s=46 An early stage custom mRNA vaccine shows promise in treating patients with pancreatic cancer. This is the technology under attack by this administration. https://t.co/4LiNGtiWDT https://x.com/andrewcaravello/status/1999164784420299058s=46 An early stage custom mRNA vaccine shows promise in treating patients with pancreatic cancer. This is the technology" [X Link](https://x.com/andrewcaravello/status/2022323884947653053) 2026-02-13T14:56Z [----] followers, [----] engagements "🧬Federal Validation of the $NWBO aDC1 #DCVax Immune Platform In October [----] the U.S. Department of Defense awarded a $22.4 million grant to the #Moffitt Cancer Center to fund a specialized clinical trial for leptomeningeal disease. This study utilizes an DC1 immune platform originally developed by researchers whose patents are now exclusively held by $NWBO. The federal funding follows nearly a decade of military-supported research into this specific dendritic-cell technology which aims to treat aggressive cancers by training a patients own immune system. By selecting this proposal over" [X Link](https://x.com/andrewcaravello/status/2022328073090158724) 2026-02-13T15:12Z [----] followers, [----] engagements "🧬 THE KALINSKI $NWBO #DCVax MASTER CIRCUIT Vaccines intratumoral live adjuvants DC-assisted adoptive T-cell therapy #Boolean execution and #PanCAN FcR-compatible PD-L1 stabilization with $AZN #durvalumab #IMFINZI 🔗 https://x.com/andrewcaravello/status/2016557539387658426s=46 Cancer changes. Your treatment should too. Too many of our loved ones have been treated with a plan made on Day [--] even when their tumor evolves resists and outsmarts that plan by month three. (1/2) https://t.co/p5V4qZKKIo https://x.com/andrewcaravello/status/2016557539387658426s=46 Cancer changes. Your treatment should" [X Link](https://x.com/andrewcaravello/status/2022349841104240660) 2026-02-13T16:39Z [----] followers, [----] engagements "@Berlinergy $NWBO #DCVax @grok explain this survival curve" [X Link](https://x.com/andrewcaravello/status/2022376678320701943) 2026-02-13T18:25Z [----] followers, [---] engagements "$NWBO #DCVax @TheRoaringKitty @MichaelJBurry__ $GME 🚗🧬 From Wolfsburg to Sawston: How Volkswagen [----] Foreshadows $NWBO [----] #DCVax 🏁 Prologue Whats New Here The Biggest Short narrative explained what happened: NWBOs peer-reviewed survival data diverged from its suppressed stock price. Spoofing documented in a https://t.co/QKQ4Bh0dfd 🚗🧬 From Wolfsburg to Sawston: How Volkswagen [----] Foreshadows $NWBO [----] #DCVax 🏁 Prologue Whats New Here The Biggest Short narrative explained what happened: NWBOs peer-reviewed survival data diverged from its suppressed stock price. Spoofing documented in" [X Link](https://x.com/andrewcaravello/status/2022428682510627118) 2026-02-13T21:52Z [----] followers, [----] engagements "❄ The Hidden Architecture When the Machine Switches On The $TMO Thermal and Industrial Gates of $MRK $EIKN $AMGN #Zeon and the $NWBO #DCVax Immune Operating System" [X Link](https://x.com/andrewcaravello/status/2022449889918226762) 2026-02-13T23:16Z [----] followers, [---] engagements "Thank you. He was a great man. Its still hard to believe he died trying to get $NWBO to the finish line. Shame on those who refuse to support a management team that has dedicated their lives not only to finding a cancer cure but to solving the scalability bottleneck that would otherwise keep that cure from ever being realized for everyone. https://twitter.com/i/web/status/2022665930275238207 https://twitter.com/i/web/status/2022665930275238207" [X Link](https://x.com/andrewcaravello/status/2022665930275238207) 2026-02-14T13:35Z [----] followers, [---] engagements "🔄🧬 The Swapbook Unwind How $NWBO and #DCVax Could Turn Synthetic Shorts Into Forced Buys TL;DR Markets dont reprice because opinions change. They reprice when constraints change. If a meaningful bearish position is being carried synthetically through derivatives the unwind wont be a narrative event. It will be a collateral event driven by margin risk limits and forced hedge adjustment in a thin market. DCVax-Ls published Phase III survival data is the clinical anchor the market can ignore while the therapy is debated science. The destabilizing moment is the category shift to approved" [X Link](https://x.com/andrewcaravello/status/2022832144230338870) 2026-02-15T00:35Z [----] followers, [---] engagements "🔄🧬 The Swapbook Unwind How $NWBO and #DCVax Could Turn Synthetic Shorts Into Forced Buys TL;DR Markets dont reprice because opinions change. They reprice when constraints change. If a meaningful bearish position is being carried synthetically through derivatives the unwind wont be a narrative event. It will be a collateral event driven by margin risk limits and forced hedge adjustment in a thin market. DCVax-Ls published Phase III survival data is the clinical anchor the market can ignore while the therapy is debated science. The destabilizing moment is the category shift to approved" [X Link](https://x.com/andrewcaravello/status/2022836903377052088) 2026-02-15T00:54Z [----] followers, [---] engagements "🧬 TLDR: The #CancerVaccine Moment: Why $NWBO #DCVax Centers the Immune Instruction Layer Therapeutic cancer vaccines are finally being treated like systems engineering not wishful antigen sprinkling. The field is shifting from one drug one lever to immune architecture because solid tumors act like an adaptive outlaw organ that defeats single-mechanism pressure by coordinating many resistance programs at once. The bottleneck is instruction. Solid tumors dont mostly fail because the immune system cant kill. They fail because the immune system often never learns the right lesson or learns it in" [X Link](https://x.com/andrewcaravello/status/2022851727326621717) 2026-02-15T01:53Z [----] followers, [---] engagements "🧬 DC-Programmed Adoptive T-Cell Therapy and Boolean Recognition DNAM-1Dependent Threshold Lowering for Low-Antigen Escape and Durable Control in $NWBO #DCVax and #EDEN-Enabled Manufacturing TLDR 📌 The main escape state is low antigen density not antigen absence. Under immune pressure many tumors remain antigen positive but drop peptideMHC display below the level needed to complete synapse formation and degranulation. T cells can register the target yet fail to execute. That corridor supports minimal residual disease dormancy and late relapse. Dong et al. define an effector phase rule that" [X Link](https://x.com/andrewcaravello/status/2022859569135833191) 2026-02-15T02:24Z [----] followers, [---] engagements "@DrPatrick @grok which cytokine is better for restoring lymphocytes Is it IL-15 or Il-7 And why" [X Link](https://x.com/andrewcaravello/status/2022881242794832326) 2026-02-15T03:50Z [----] followers, [--] engagements "Those are not randomized trials isolating IL-15 as the independent variable. Single-arm or combination studies cannot prove that correcting lymphopenia caused the survival difference. Where is the randomized trial in patients selected for low ALC where IL-15 alone added to an otherwise identical control arm improved overall survival If that study does not exist then ALC correction with IL-15 remains a pharmacodynamic effect not a validated mortality intervention. https://twitter.com/i/web/status/2022892611371937797 https://twitter.com/i/web/status/2022892611371937797" [X Link](https://x.com/andrewcaravello/status/2022892611371937797) 2026-02-15T04:35Z [----] followers, [--] engagements "Thanks that answers it. [--]. If the 21.1-month mOS is from a single-arm Phase 2b with a historical comparator its a signal not proof. Historical [--] month docetaxel benchmarks are not a valid efficacy control without matching for line of therapy performance status PD-L1 status steroid exposure tumor burden and co-treatments. [--]. You confirm theres no detailed baseline matching. That means the vs [--] months comparison is not causal. [--]. You also confirm ALC [----] is not a validated surrogate endpoint for survival by FDA or guidelines. So 60% hit ALC [----] is pharmacodynamic context not an approvable" [X Link](https://x.com/andrewcaravello/status/2022916206307508735) 2026-02-15T06:09Z [----] followers, [--] engagements "🔬 The Hidden Engine Behind $NWBO Global Vision: The Flaskworks Patent Everyones focused on DCVax-L. But if NWBO truly scales worldwide like $AMZN Web Services (AWS) it will be because of a machine described in one breakthrough patent: 📄 WO2020/102062 Dendritic Cell Generating Apparatus and Method Not just hardware. Its a complete programmable manufacturing platform for personalized immune therapy. Designed to work anywhere. Enforced by design. Heres what it actually does and why it matters 👇 🧪 What the Patent Describes (And Why Its Revolutionary) The Flaskworks system is a closed-loop" [X Link](https://x.com/anyuser/status/1930502977468420204) 2025-06-05T05:52Z [----] followers, [----] engagements "$NWBO 🧵 In Vivo T Cell Activation The DCVax-Direct Approach Most cell therapies reprogram T cells in a lab. DCVax-Direct does it differently: it trains the immune system inside the tumor where the battle is actually happening. Heres how it works 👇 🧬 DCVax-Direct Mechanism of Action tumor injection Dendritic cells (DCs) are injected directly into the tumor site. 2.On-site antigen sampling These DCs collect live tumor antigens in vivo no need to predefine targets. 3.Immune activation at the source The injection creates local inflammation drawing in immune cells and breaking immune silence." [X Link](https://x.com/anyuser/status/1931341053249921191) 2025-06-07T13:22Z [----] followers, [----] engagements "Victorious warriors win first and then go to war while defeated warriors go to war first and then seek to win. - Sun Tzu The Art of War Thats $NWBO. They didnt chase the moment they built the framework: Personalized immune therapy Patient-specific manufacturing Survival-based endpoints A platform rooted in safety science and time They endured dilution disbelief manipulation and stayed aligned to a model the system wasnt ready to accept. Now the system is evolving around them. ✔ MHRA conditional pathways ✔ FDA cell & gene therapy reform ✔ Industry shift toward mechanism-based approval ✔" [X Link](https://x.com/anyuser/status/1931371280311177381) 2025-06-07T15:22Z [----] followers, [----] engagements "$NWBO 🧠 DCVax-L DCVax-Direct and the Hiltonol Combo Trial: Immune Platforms That Preceded the Framework Now Perfectly Fit These trials werent delayed or deficient they were clinically complete scientifically ahead and simply built before the regulatory system was mature enough to interpret them. Thats no longer the case. Its not that these therapies failed to generate data. Its that we didnt have a regulatory process that knew how to receive it. - FDA CBER [----] Were looking at how to support real-world evidence mechanistic rationale and immune-based endpoints particularly in personalized" [X Link](https://x.com/anyuser/status/1931453927406616661) 2025-06-07T20:51Z [----] followers, [----] engagements "Guess $NWBO was at #ASCO25 after all 🧠💉 NWBO's In-Licensed DC1 Dendritic Cell Platform Advances in Breast Cancer Brain Mets Trial at ASCO [----] 📢 The Phase IIa trial (NCT04348747) investigates a dendritic cell-based vaccine called DC1 loaded with HER2/HER3 peptides and combined with the immune checkpoint inhibitor pembrolizumab (antiPD-1) in patients with asymptomatic brain metastases from HER2/HER3+ breast cancer. Key Biological Components: DC1: A polarized dendritic cell type developed through ex vivo exposure to a Th1-polarizing cytokine cocktail (IL-1 TNF- IFN- IFN- and poly-I:C) as" [X Link](https://x.com/anyuser/status/1932498527852036575) 2025-06-10T18:02Z [----] followers, 12.8K engagements "$NWBO An Eagles Eye View: The Quiet Activation Simply Explained In June [----] a series of public events take place across several countries. On their own each one might seem routine. Together they reveal something more: The infrastructure needed to deliver personalized immune therapieslike DCVax-Lis not just being planned. It appears to be quietly going live. No fanfare. No announcements. Just alignment. 🔬 What Is DCVax-L DCVax-L is a personalized cancer treatment developed by Northwest Biotherapeutics. Its designed for people with brain cancer specifically glioblastoma. It works by taking a" [X Link](https://x.com/anyuser/status/1932938680055861265) 2025-06-11T23:11Z [----] followers, 71.1K engagements "$NWBO The Quiet Evolution of DCVax: What UCLA Just Confirmed Without Saying UCLA just released a major update on their brain cancer research and if youve been following the science behind DCVax whats buried in that update speaks louder than anything on the surface. Lets start here: the dendritic cell vaccine UCLA uses in their program is called ATL DC. It doesnt carry the DCVax name but its built on the same backbone. Same inventors. Same tumor lysate process. Same dendritic cell prep. Its the academic version of what became DCVax-L. And back in [----] UCLA published results in Nature" [X Link](https://x.com/anyuser/status/1933548778222505994) 2025-06-13T15:35Z [----] followers, [----] engagements "$NWBO just closed above both its 50-day and 200-day moving averages at $0.2779. If price holds above $0.28 on Monday June [--] a golden cross could officially trigger when the 50-day average crosses above the 200-day. Its a classic bullish signal that often marks a long-term trend reversal. To confirm it: Price needs to stay at or above current levels Volume needs to hold or increase The 50-day MA must cross upward through the 200-day MA And if it happens on the same day MHRAs new cell therapy rules go live and global regulators align at DIA Thats not just technical. Thats timing. $NWBO [--] Gen💰" [X Link](https://x.com/anyuser/status/1933617714846634254) 2025-06-13T20:09Z [----] followers, [----] engagements "🕯 The Hidden Legacy of Dr. Linda Liau: What We Miss About DCVax-L With deep thanks to $NWBO community members and truthseekersespecially @d_stock07734 persistence brings long-buried facts to light. Until now almost no one knew this story. It was hidden in plain sight. And it changes everything. 🧩 We think we know the story of DCVax-L. But were only just beginning to understand it. Everyone knows about the Phase [--] trial. Many know about the publication in Nature Communications. But almost no one realizes that some of the most important evidence for DCVax-Ls promise comes not from 2022but" [X Link](https://x.com/anyuser/status/1933722811249377308) 2025-06-14T03:06Z [----] followers, 10.7K engagements "$NWBO Why the UK Moved First: 🧬 The System That Was Quietly Built Around DCVax There are moments in medicine when the science arrives before the world is ready. DCVax-L was one of those. This wasnt a typical cancer drug. It didnt attack the tumor with poison. It didnt hammer the immune system into confusion. It taught the body to do what it was built to do: recognize respond remember. DCVax-L is made from a patients own dendritic cells immune cells whose job is to train the immune system. Theyre collected educated using tumor antigens and re-infused into the patient. What comes next isnt" [X Link](https://x.com/anyuser/status/1933755144228815017) 2025-06-14T05:15Z [----] followers, 11.1K engagements "$NWBO 🧬 Supercharging the Immune Engine: What Dr. Boschs NYAS Lecture Means for the Future of DCVax 📖 Note: This is a long immersive read (1015 minutes). Its not meant to be skimmed. Each section builds on the lastskip ahead and youll miss the structure and implications of whats unfolding. Dr. Marnix Boschs upcoming talk at the New York Academy of Sciences isnt just another update on dendritic cell vaccinesits a reveal. A reframe. A reset of expectations around how far the DCVax platform can go. Many people already know what DCVax is. What they may not yet see is how its evolvingand how its" [X Link](https://x.com/anyuser/status/1934191507814133891) 2025-06-15T10:09Z [----] followers, 37.6K engagements "$NWBO 🧠HER2 Is the Proof. DCVax Is the Platform. What Happens Next Is Crystal Clear. In [----] Dr. Crystal Mackall and her team at Stanford launched a first-in-human CART cell trial targeting HER2-positive brain tumors in pediatric and young adult patients. 📎 NCT03500991 No vaccine. No IL12. No IL7. No intracellular delivery system. Just one question: Can HER2 be safely and effectively targeted inside the brain ✅ Yes HER2 was actionable ✅ Yes engineered T cells crossed the bloodbrain barrier ✅ Yes tumor responses occurred without neurotoxicity This trial didnt try to build the full immune" [X Link](https://x.com/anyuser/status/1934345659290730586) 2025-06-15T20:21Z [----] followers, [----] engagements "$NWBO We all came into this at different times. Some of you have been here longer than I have. Others are just getting started. Im probably somewhere in the middle. But I think right now more than anything we need to zoom out. This isnt the moment to worry. This is the moment to pause take a breath and let the process play out. Everything is already shifting. Not in theory but in real time. Its happening because something this big doesnt move the same way as everything else. The system is already bending around it. I dont spend time anymore wondering if this will get approved. I believe its" [X Link](https://x.com/anyuser/status/1934655108849053757) 2025-06-16T16:51Z [----] followers, [----] engagements "WE GOT PUNKED BUT SO DID THE SHORTS A masterclass in regulatory discipline disguised as disappointment. 🧨 The Setup All signs pointed to a $NWBO showcase week: Bosch speaking at NYAS on June [--] The UKs MHRA launching its decentralized ATMP manufacturing framework on June [--] Bosch presenting again at BNOS on June [--] The talk title: Next Generation Dendritic Cells to Improve Anti-Tumor Responses Expectations were high. The narrative was primed for: New cytokine-enhanced DC1 data Integration of Flaskworks automation Expanded trial designs An immune stack rollout A full-circle" [X Link](https://x.com/anyuser/status/1934808136600146420) 2025-06-17T02:59Z [----] followers, [----] engagements "🚨 THREAD: The FDA Just Changed the Game and $NWBO Might Already Be on the Field On June [--] [----] the FDA launched its most aggressive review pathway in history: the Commissioners National Priority Voucher (CNPV). It compresses approval from [----] months to just [--] months for companies aligned with U.S. national priorities. And $NWBO isnt just a match they may already be moving through the gate 🧵 🔹 What is the CNPV A voucher-based system that replaces traditional FDA review with a 1-day tumor board style panel mirroring real-world multidisciplinary care. Instead of fragmented review across" [X Link](https://x.com/anyuser/status/1934995920090800360) 2025-06-17T15:25Z [----] followers, 10.4K engagements "$NWBO 🧠 The Plan Was [--] Years. The Trial Took [--]. Timing Is a Funny Thing. You probably didnt hear it on the news but on June [--] [----] the U.K. quietly launched the most sweeping overhaul of its clinical research system in history. No fanfare no headlines no televised rollout. Just a 7-page release on without a press conference. Yet it changes everything. This new 10-Year Health Plan introduced the same day the FDA launched its CNPV fast-track program is a system-wide green light for trials like DCVax-L. The MHRA didnt just clear its backlog. It publicly stated it would now focus its" [X Link](https://x.com/anyuser/status/1935092750346519036) 2025-06-17T21:50Z [----] followers, [----] engagements "$NWBO 🧾 Statutory Instrument [----] No. 87: The Law is Already in Force 🔹 Title: The Human Medicines (Clinical Trials and Advanced Therapy Medicinal Products) (Amendment) Regulations [----] 🔹 Reference: SI [----] No. [--] 🔹 Governing Body: UK Parliament / MHRA 🔹 Publication Date: March [--] [----] 🔹 Effective Date (Legal Commencement): June [--] [----] 🔹 Compliance Enforcement Begins: July [--] [----] 🔍 Breakdown of the Key Dates ✅ June [--] [----] The Law Is Active This is the coming into force date written directly into the legislation. From this day forward the updated regulatory framework is live. Any" [X Link](https://x.com/anyuser/status/1935277958463094790) 2025-06-18T10:06Z [----] followers, [----] engagements "$NWBO The Platform Is Ready: How MHRA NICE and Flaskworks Have Paved the Way for Scalable Cell Therapy 🧬 [--]. THE PATIENT JOURNEY: What It Looks Like Now Imagine youre diagnosed with glioblastoma in the UK. Before: You enroll in a trial. Your blood is shipped across the country (or ocean). Manufacturing takes weeks. Meanwhile your tumor grows. The logistics are fragile. The cost Enormous. Now under the new MHRA framework made law by SI [----] No. [--] heres what happens: ✅ You go to a certified NHS hospital. ✅ Your blood is drawn and stays on-site. ✅ Flaskworks a closed automated" [X Link](https://x.com/anyuser/status/1935489732152017158) 2025-06-19T00:08Z [----] followers, 54.4K engagements "$NWBO 🧬 DCVax-L the EDEN System and the Law That Changes Everything A quiet revolution in medicine is now fully built. The treatment is ready. The system is ready. The law is now in effect. The only thing left is final approval. Here is the complete story of DCVax-L the EDEN device and the new legal pathway that will allow them to treat patients. [--]. The Treatment: DCVax-L is Personalized Immune Therapy DCVax-L is not a standard drug. It is not mass produced. It is not a chemical pill or a general injection. It is made for each individual patient using their own immune system. These" [X Link](https://x.com/anyuser/status/1936193123794710707) 2025-06-20T22:43Z [----] followers, [----] engagements "🌀 How $NWBO Quietly Assembled Full Control of the Immune Stack 💫 ✨ Introduction: The Immunotherapy Puzzle That Was Hiding in Plain Sight Northwest Biotherapeutics (NWBO) long viewed as the quiet steward of DCVax-L has been underestimated for years as a single-product biotech. But a full review of clinical data patent filings regulatory disclosures and strategic acquisitions reveals something far more ambitious: NWBO has not just developed a vaccine they have engineered an entire immune stack. 🧬 That architecture was first revealed in coded form during Dr. Marnix Boschs [----] NYAS" [X Link](https://x.com/anyuser/status/1937096399117602918) 2025-06-23T10:32Z [----] followers, [----] engagements "$NWBO ✅ The Regulatory Greenlight: MHRAs June [----] Corporate Plan Confirms DCVax L Is Positioned for Approval On June [--] [----] the UKs MHRA published its updated Corporate Plan. This update provides clear alignment between the agencys current regulatory framework and the technical operational and clinical characteristics of decentralized immunotherapies such as DCVax L and Flaskworks. The necessary infrastructure is in place. The governing legislation is now active. The regulatory strategy outlined in the Corporate Plan reflects the core elements of the DCVax platform. This update indicates" [X Link](https://x.com/anyuser/status/1937957980223508720) 2025-06-25T19:36Z [----] followers, [----] engagements "$NWBO 🧨 This Study Didnt Elevate DCVax It Eliminated Everything Else A new peer-reviewed study published in Nature Communications has done what few papers ever accomplish: it exposed the entire battlefield. 📖 Full study: It used advanced spatial transcriptomics exome sequencing and tumor-normal analysis across [--] glioma tumors to build a multidimensional map of how glioblastoma actually behaves inside the human body. And what it found quietly rewrites the rules of treatment. This wasnt a step forward for drug development. It was a hard stop for almost everything else. Without ever" [X Link](https://x.com/anyuser/status/1938424109471269120) 2025-06-27T02:28Z [----] followers, [----] engagements "$NWBO 🧩 [--]. What the MHRA Actually Says In official guidance legal reforms (SI [----] No. 87) and strategic briefings especially the July [--] [----] Point-of-Care Manufacturing Consultation the MHRA repeatedly highlights its top priority: Personally Individualised Cancer Vaccines (PICVs) They define these as: Therapies manufactured at the point of care tailored from the patients own cells or tumour material intended to activate an immune response against unique tumour neoantigens. That definition does not describe mRNA. It describes a personalized cell-based immunotherapy built from the patients" [X Link](https://x.com/anyuser/status/1938935344713330825) 2025-06-28T12:19Z [----] followers, [----] engagements "$NWBO 🧠 They Just Discovered What DCVax Already Fixed A new Nature paper just announced something they think is groundbreaking: dendritic cells (DCs) the immune systems scouts cant move inside tumors. According to the researchers as cancers grow the tumor microenvironment shuts down nitric oxide which shuts down soluble guanylyl cyclase which shuts down cGMP which shuts down myosin-II the little molecular engine DCs use to crawl. With that system offline dendritic cells cant get from the tumor to the lymph nodes to alert the T cells. And if the T cells dont get the message the immune system" [X Link](https://x.com/anyuser/status/1938958632516759811) 2025-06-28T13:52Z [----] followers, [----] engagements "$NWBO 🧠 Why the [--] Billion Dollar Merck and Daiichi Deal Might Be Just the Beginning of Something Much Larger: #DCVax In [----] Merck paid [--] billion dollars to co-develop three antibody drug conjugates from Daiichi Sankyo. That included [--] billion upfront [---] billion in options and the rest tied to milestones. The message was clear. Merck was assembling a next-generation cancer stack. But despite its size that deal did not include the most important layer the adaptive immune intelligence that tells you what to target in the first place. That layer is DCVax. 🎯 What ADCs Are Designed to Do and" [X Link](https://x.com/anyuser/status/1939407838914220049) 2025-06-29T19:37Z [----] followers, [----] engagements "$NWBO 🧠 DCVax-L: A New Era for Brain Cancer Could Begin Right Now Glioblastoma patients are still being told the same thing today they were told [--] years ago theres nothing more we can do. No cure. No real options. Median survival remains under [--] months. At recurrence it drops even further. And for most clinical trials are out of reach. But DCVax-L could finally change that. DCVax-L is a personalized dendritic cell vaccine made from the patients own tumor. It trains the immune system to recognize and attack what surgery and chemo leave behind. The science is real. The data is peer-reviewed." [X Link](https://x.com/anyuser/status/1939750935863205899) 2025-06-30T18:20Z [----] followers, [----] engagements "$NWBO When the Manufacturer Speaks Without Saying the Name Mike Scott President of Advent Bioservices just posted a quiet thunderclap. He shared a Times article titled Patients to get new drugs sooner under plan to slash NHS red tape To the casual reader it sounds like generic reform talk. But this is not generic. And this is not casual. This is a statement from the President of the only GMP manufacturer in the United Kingdom that is authorized to produce one specific therapy. Advent Bioservices manufactures only one drug. That drug is DC Vax-L. They do not make CAR T cells. They do not make" [X Link](https://x.com/anyuser/status/1940033256390271050) 2025-07-01T13:02Z [----] followers, 10.2K engagements "$NWBO Hey @adamfeuerstein appreciate the stylistic compliment. I guess great minds think alike. If you or anyone else has further questions feel free to direct them to legal @CohenMilstein can take it from here 😉" [X Link](https://x.com/anyuser/status/1940738377894318171) 2025-07-03T11:44Z [----] followers, 28.7K engagements "$NWBO 🧬 The Hidden Gem in Plain Sight: A Landmark [----] Immunotherapy Review Quietly Reframing DCVax-Ls Role in Glioblastoma and Beyond Sometimes the most significant validations arrive without a press release without a banner and without even a whisper in the noise of biotech speculation. That is exactly what happened on March [--] [----] when Cancer Science the official journal of the Japanese Cancer Association published a paper that may become one of the most strategically relevant reviews in the entire immunotherapy landscape for glioblastoma. The paper is titled Opportunities to Modulate" [X Link](https://x.com/anyuser/status/1940813449782612091) 2025-07-03T16:42Z [----] followers, [----] engagements "$NWBO 🛸 The Signal That Was Jammed by $MRK (Part Deux) How Three Dendritic Cell Trials in Colorectal Cancer Were Silenced (Until They Werent) 🗞 Why I Deleted the Original Post On July [--] I deleted the first version of this post originally titled The Signal That Was Jammed. It was based on a promising but misdirected listing (NCT03735290) that pointed to a different terminated study a basket trial using an allogeneic dendritic cell vaccine with checkpoint inhibitors in cold tumors like gastric and gastroesophageal junctional adenocarcinomas. It wasnt the Roswell colorectal trial I was looking" [X Link](https://x.com/anyuser/status/1943273438153433431) 2025-07-10T11:37Z [----] followers, [----] engagements "🧠 $NWBO and the New Era for Glioblastoma: What Just Became Possible Today We dont just want to see hope for glioblastoma victims. We want to see hope for the victims of all rare cancers by starting with glioblastoma we start with the worst. Siobhain McDonagh MP for Mitcham and Morden House of Commons speech on the Rare Cancers Bill July 11th [----] ⚡ TL;DR July 2025: The Regulatory Walls Just Moved The Rare Cancers Bill has now passed unamended through the House of Commons enshrining into law a national overhaul of how the UK handles rare cancers like glioblastoma. Combined with MHRAs" [X Link](https://x.com/anyuser/status/1943708425478680916) 2025-07-11T16:26Z [----] followers, [----] engagements "Heres a clean factual breakdown of why $NWBO controls the entire autologous dendritic cell platform (legally scientifically and commercially) All sources are verifiable. 🕰 Estimated read time: 10-12 min Intellectual Property Ownership of Autologous Dendritic Cell Methods for Cancer Immunotherapy Overview: The immunotherapeutic method involving autologous dendritic cells (DCs) pulsed ex vivo with tumor lysate is a clinically tested approach protected by intellectual property (IP) rights. Critically the tumor lysate itself whether autologous or pooled allogeneic is not patentable as it is a" [X Link](https://x.com/anyuser/status/1944109981717967106) 2025-07-12T19:01Z [----] followers, [----] engagements "Asked what breakthroughs he hopes to see as FDA Commissioner Dr. Makary described a therapy that makes stage [--] cancer melt away: no chemo no surgery no radiation. He didnt name it. But if you know $NWBO and #DCVax you know exactly what just happened. 🕯 #CancerImmunotherapy #Glioblastoma #Biotech #FDA #PrecisionMedicine #Immunotherapy #CellTherapy $IBRX $IMUX $MRNA $BNTX $TCRT $VCNX $NVS FDA Commissioner @DrMakaryFDA talks about promising treatments in the pipeline and the innovations and breakthroughs hed like to see in the future. https://t.co/KdJKF8QB0w FDA Commissioner @DrMakaryFDA talks" [X Link](https://x.com/anyuser/status/1944259156652802082) 2025-07-13T04:54Z [----] followers, [----] engagements "$NWBO DCVax-L Gains First Ever Recognition in the Academic Oncology Framework for Glioblastoma 🧠💉📊 A July [----] radiotherapy review authored by oncology experts from Spain marks a material shift in how #DCVax-L is positioned within the treatment discourse for glioblastoma. For the first time a peer facing academic publication has included DCVax-L in a structured immunotherapy comparison table alongside checkpoint inhibitors oncolytic viruses vaccine platforms and cytokine based therapies. The table presents phase III data with median overall survival of [----] months in recurrent GBM (rGBM" [X Link](https://x.com/anyuser/status/1944763287830163757) 2025-07-14T14:17Z [----] followers, [----] engagements "$NWBO 🧠 Part [--] of 2: The Silent Stack How Mayo Quietly Reproduced the DCVax Immune Engine Trial by Trial 🪶TL;DR 🕰 Estimated Read Time: [----] minutes 🎗 #GlioblastomaAwarenessDay The Silent Stack explores how Mayo Clinic has effectively validated Northwest Biotherapeutics DCVax immune platform without ever naming it. Through a series of independently executed trials using pooled tumor lysate and matured dendritic cells Mayo reproduced the precise immune architecture survival outcomes and tumor-agnostic versatility long associated with DCVax. Dr. Marnix Boschs [----] Matrix outlines how the" [X Link](https://x.com/anyuser/status/1945505349844316627) 2025-07-16T15:26Z [----] followers, [----] engagements "This could be a new record for $NWBO with an 80.11% short ratio. How is this level of short interest permitted or even possible without manipulation @DOGE_SEC @SECGov @CohenMilstein NWBO REPORTED SHORT SHARES TODAY 80.11% How many naked shorts shares Dark Pool https://t.co/7cBaO5XLkg NWBO REPORTED SHORT SHARES TODAY 80.11% How many naked shorts shares Dark Pool https://t.co/7cBaO5XLkg" [X Link](https://x.com/anyuser/status/1945786828721660041) 2025-07-17T10:05Z [----] followers, [----] engagements "🩸How $NWBO Integrated Platelet Biology Dendritic Cell Licensing and a Silent Immune Engine Estimated Reading Time: [----] minutes 🧪 TL;DR: The Engine Behind the Silence Mill Creeks PLTMax produces pooled tumor lysate rich in vascular antigens. Mayo proved the lysate works when combined with dendritic cells prepared using Northwest Biotherapeutics method. The trial succeeded without naming the company but the immune engine was theirs. Mill Creek owns the reagent. Mayo confirmed the system. Northwest Biotherapeutics owns the method. Flaskworks automates it. SI [--] enables delivery. The trial" [X Link](https://x.com/anyuser/status/1946078002950873340) 2025-07-18T05:22Z [----] followers, [----] engagements "🚨 $NWBO Can Start Now: DCVax-L Fits the FDAs Fastest Review Track Ever 🚨 Today marks a turning point: the FDA is officially accepting applications for its new Commissioners National Priority Voucher (CNPV) pilot a program offering [--] month reviews and real-time agency engagement for therapies that serve a national public health need. And DCVax-L may be one of the most eligible candidates in the country. 🧩 What the CNPV Pilot Offers [--] month rolling review 🔁 Live tumor boardstyle communication with FDA 🧬 Support for cutting-edge personalized immunotherapies 🏁 Early-stage eligibility" [X Link](https://x.com/anyuser/status/1947731433193193492) 2025-07-22T18:52Z [----] followers, [----] engagements "🔱 $NWBO Owns the Method. And the Trial Already Proved It Works. Dr. Marty Makary described the future. A therapy that makes stage [--] cancer melt away. No chemo. No radiation. No surgery. But what if that wasnt a dream What if it already happened What if the method was already validated And what if NWBO owns it Because it did. It is. And they do. 🔬 One of Many Trials That Proved It Could Be Done At Mayo Clinic in a Phase I/II study for relapsed and refractory non-Hodgkin lymphoma patients were treated without chemotherapy or radiation. These werent early-stage patients. They had failed" [X Link](https://x.com/anyuser/status/1951832710915236337) 2025-08-03T02:29Z [----] followers, [----] engagements "🧬 Mayo Validated the Method. The Full Signal Was Overlooked Until Now 100% survival. No chemo. And a quiet trial that may have just locked the IP behind $NWBO immune OS with $MRK infrastructure waiting. Lets set the record straight. An earlier version of this post cited an [----] percent five-year survival rate for the Mayo Clinic lymphoma trial. That was based on a reasonable interpretation of partial data but after reviewing the full results it turns out the truth is even stronger. 💡 One hundred percent of patients in the trial were alive at the five-year mark. Every single one. And that" [X Link](https://x.com/anyuser/status/1952356349116883167) 2025-08-04T13:10Z [----] followers, [----] engagements "$NWBO Is Entering the Final Regulatory Sequence in the UK The MHRA and NICE have now merged their review tracks. Licensure and reimbursement will now be processed in parallel. This removes the final bottleneck between MHRA approval and NHS access. 📎 For NWBO which already has live GMP manufacturing under SI [--] and real-world deployment through IFR and Specials this is not just policy alignment. It is system readiness. On July [--] NICE confirmed NWBO is fully engaged in the MHRA Marketing Authorisation Application process but has not yet submitted to NICE. That is not delay. That is" [X Link](https://x.com/anyuser/status/1953160310983938482) 2025-08-06T18:24Z [----] followers, [----] engagements "🚀 #DCVax $NWBO 10-Q: $MRK Winterfell 🏰 #Eden 🧬 UKUS Manufacturing Buildout and the Retail Storm to Come TLDR: In the same way $GME surge @TheRoaringKitty calls and @wallstreetbets rallies showed what can happen when thin floats concentrated retail holders and heavy short pressure meet a catalyst NWBOs June [--] [----] 10-Q reveals a setup with similar structural energy but built on very different foundations. This is intentionally a dense detail-driven read because the case rests on tangible infrastructure and regulatory positioning not just sentiment. The filing shows the DCVax platform being" [X Link](https://x.com/anyuser/status/1956171067946381559) 2025-08-15T01:48Z [----] followers, [----] engagements "⚠ Quick check can everyone see my $NWBO #DCVax posts My account was temporarily restricted and I had to verify. Sorry to keep asking just want to make sure nothing is being hidden" [X Link](https://x.com/anyuser/status/1960228483470152114) 2025-08-26T06:31Z [----] followers, [----] engagements "🔥🏰 $NWBO #DCVax Dividends hand out coins. Linda Powers gave shareholders the Fire of Valyria. Heres why Advents sale into NWBO was the greatest gift any CEO has ever given 👇" [X Link](https://x.com/anyuser/status/1960970145041465734) 2025-08-28T07:38Z [----] followers, [----] engagements "⚖🔥 Spoofing Is Now Fraud: Why $NWBO Case Just Went Nuclear 🎯 The Turning Point On August [--] [----] the Seventh Circuit Court of Appeals handed down a ruling in United States v. Smith that will reverberate through Wall Street for decades. The court held unequivocally that spoofing = fraud. For years market makers argued spoofing was just bad form not deception. That loophole is gone. Submitting orders you intend to cancel is now fraud in federal law. This is not abstract. It detonates directly inside the heart of $NWBOs ongoing lawsuit against Citadel Canaccord Susquehanna and the other" [X Link](https://x.com/anyuser/status/1961421987496005823) 2025-08-29T13:33Z [----] followers, [----] engagements "🚨 Breaking Sept [--] 2025: FDA Creates Rare Disease Evidence Path That Fits $NWBO #DCVax Today the FDA unveiled the Rare Disease Evidence Principles (RDEP) codifying that ONE adequate well-controlled trial plus confirmatory evidence can be enough for approval . 👉 Confirmatory evidence can include: Mechanistic or biomarker data Natural history comparators Clinical pharmacodynamics Expanded access / Specials data Case reports & peer-reviewed publications This is the exact evidence architecture that $NWBO #DCVax already has: Phase III GBM trial (adequate controlled peer-reviewed) Mechanistic data" [X Link](https://x.com/anyuser/status/1963316713249726524) 2025-09-03T19:02Z [----] followers, [----] engagements "🎗 The $NWBO #DCVax Hidden Gate in Action (Part [--] of 2): How Caveolin-1 Proves Durable Survival Through Gates [--] and [--] TLDR Part [--] revealed the first hidden gate: teaching. Caveolin-1 (CAV1) was shown to be indispensable for dendritic cells to reach lymph nodes deliver their lessons and seed immune memory. That discovery first uncovered in [----] preclinical work and then validated in patients in [----] explained why DCVax has achieved survival plateaus where other vaccines failed. Here in Part [--] the map of the fortress expands. CAV1 also governs: Gate [--] Access. Memory T cells must cross vascular" [X Link](https://x.com/andrewcaravello/status/1967923260659511662) 2025-09-16T12:07Z [----] followers, [----] engagements "@ablidy your work at the Becton Dickinson Monoclonal Center was not just technical support for immunology. It fundamentally changed what the immune system could be seen to be doing. Through early multicolor flow cytometry PE conjugation and careful quantitative analysis you and your colleagues showed that key immune markers like CD25 are not simply on or off. They exist at low stable baseline levels in normal cells. And those levels matter. That insight sounds obvious today. It was not obvious then. By making low level CD25 expression measurable in normal human CD4 T cells BDMC gave" [X Link](https://x.com/andrewcaravello/status/1999938829751603230) 2025-12-13T20:25Z [----] followers, [---] engagements "If you care about glioblastoma Brain Tumor Awareness Month starts here. This isnt hypeits about a therapy that survived against all odds. An amazing piece by @AndrewEcker829 . Read it. Share it. The system tried to bury this: #BrainTumorAwarenessMonth Highlights 🧠 #Glioblastoma 🎗 #BrainTumorAwareness #BTAM ⚕ #NeuroOncology #CancerResearch #Immunotherapy 📊 #DCVax $NWBO ✊ #EndBrainCancer #GBMawareness #CancerAwareness Tagging the frontline voices @NBTStweets @braintumororg @EndBrainCancer @ABTA @TheBTL @brainstrust @braincancerfdn @CancerResearch @CNNCancerDoc @oncology_bg @braintumourrsch" [X Link](https://x.com/andrewcaravello/status/1918661708433805390) 2025-05-03T13:39Z [----] followers, 1M engagements "$NWBO The Elephant in the Room: DCVax-L Merck and the Quiet Mobilization of a Global Immunotherapy Framework [---] Days of Silence and Still No Refusal DCVax-L the worlds most advanced autologous dendritic cell therapy for glioblastoma passed MHRA validation [---] days ago. Accounting for RFI pauses (60120 days) the regulatory review clock has far exceeded the 210-day norm with no Refusal to Grant (RTG) issued. No 8-K. No withdrawal. No red flags. This silence doesnt indicate rejectionit indicates complexity. Possibly coordination. Possibly scale. And yetMercks [----] Annual Shareholder Meeting" [X Link](https://x.com/andrewcaravello/status/1927456607023095974) 2025-05-27T20:07Z [----] followers, [----] engagements "$NWBO This slide from Biomedtracker (April 2025) confirms that: DCVax-Ls UK Approval Decision is officially expected between March [--] and June [--] [----]. 🔍 Key Insights: Label Listed: Brain Cancer (Malignant Glioma; AA and glioblastoma GBM) showing potential for both Grade III (Anaplastic Astrocytoma) and Grade IV (GBM) not just GBM alone. Placement Among High-Impact Therapies: DCVax-L is listed alongside gene therapies CAR-Ts and rare disease biologicsimplying Citeline sees it as a high-priority regulatory catalyst. Source Credibility: This is compiled by Citeline and shared through the" [X Link](https://x.com/andrewcaravello/status/1927733098768163113) 2025-05-28T14:26Z [----] followers, [----] engagements "The Question of All Questions: What Do [---] Billion Shares Actually Own in a Debt-Free $NWBO ⚖ Context Shift A company with [---] billion outstanding shares may seem bloated until the debt is fully cleared regulatory approval is imminent and that share base now owns: A validated personalized cancer vaccine A tissue-agnostic immunotherapy platform Fully built manufacturing infrastructure IP that can be franchised globally And the potential to treat tens of thousands of patients annually Lets walk through the numbers platform scope and strategic leverage that redefine NWBOs valuation math. 🔍 1." [X Link](https://x.com/andrewcaravello/status/1928448667817509288) 2025-05-30T13:49Z [----] followers, 17.9K engagements "$NWBO 🚀 The Tilt Heard Round the World: Flaskworks New Patent Rewrites the Playbook for Cell Therapy Automation (Expert-Level Analysis of WO2025/106534 A1 Published May [--] 2025) And yes📢 a shoutout again to Henry Mooney for delivering another infrastructure-defining upgrade behind the scenes. 🧬 What It Is WO2025/106534 is a new Flaskworks patent that introduces a precision mechanical system for automated GMP-compliant rotation tilt and agitation of bioreactors during the manufacturing of cellular therapies. This extends Flaskworks intellectual footprint beyond enclosed culture to include" [X Link](https://x.com/andrewcaravello/status/1930674926366720282) 2025-06-05T17:15Z [----] followers, [----] engagements "💣 $NWBO Legal Endgame Just Found Its Blueprint And Its Already Trading at a 22% Premium Quantum BioPharma (NASDAQ: QNTM) just detonated a playbook NWBO can follow and possibly exceed. On June [--] [----] QNTM announced a Contingent Value Rights (CVR) dividend tied to its ongoing spoofing lawsuit against CIBC and RBC. Each CVR grants shareholders 10%50% of any net recovery if litigation succeeds. The CVRs are: 1:1 per common share Non-transferable non-dilutive non-voting Cash-settled only if Quantum wins or settles Enforceable and unlinked from market price swings In [--] hours Quantum shares" [X Link](https://x.com/andrewcaravello/status/1935016424474558934) 2025-06-17T16:47Z [----] followers, [----] engagements "🔮 Why DCVax Cannot Be Skipped $NWBO And Why Adam Feuerstein Fears It Based on everything weve seen regulatory behavior public statements structural reforms and the groundwork already laid there is a compelling case that DCVax-L should receive MHRA approval before the final FDA CEO forum on July [--] [----]. This isnt speculation. Its what @adamfeuerstein has been trying to suppress and as @AndrewEcker829 brilliantly explains in The Silence Before the Snap its why so many biotech gatekeepers have gone quiet because the moment DCVax gets approved the old playbook breaks. 📎 The Silence Before the" [X Link](https://x.com/andrewcaravello/status/1935665256044388449) 2025-06-19T11:45Z [----] followers, [----] engagements "To Whom It May Concern Im not here to argue with trolls. Im here because this matters. $NWBO matters Im a board certified emergency and internal medicine physician. Ive worked countless night shifts helping people through their worst moments then spent my days building something of my own. That something is a wellness and weight loss clinic I opened under the Medi-Weightloss brand. Within a year I was asked to serve as Vice President of the Medi-Weightloss National Advisory Committee due to the consistently strong clinical outcomes at my clinic. While I no longer hold that role I remain an" [X Link](https://x.com/andrewcaravello/status/1942466564231406036) 2025-07-08T06:11Z [----] followers, 10.5K engagements "📘 $NWBO $MRK: The Textbook and the Teacher & How #DCVAX-L Quietly Rewrote the Rules of Cancer Vaccines 📢 TLDR: Most people think DCVAX L is a personalized tumor vaccine but that is not exactly true. The real genius is that it trains your immune system using a prebuilt tumor lysate library without needing a fresh tumor sample. The personalization comes not from the tumor but from the dendritic cells which must be your own. This design changes everything. It is scalable efficient and still fully individualized. 🧬 The Lysate is Shared For years people assumed the power of DCVAX came from" [X Link](https://x.com/andrewcaravello/status/1942737738991567274) 2025-07-09T00:09Z [----] followers, [----] engagements "🧠Strategic Convergence: Yorkville $NWBO Indaptus and Modular Immune Architecture 📡 TL;DR (22-25 min read): Yorkvilles dual financing of NWBO and $INDP reveals a deeper strategy: the rise of a programmable immunotherapy system. #DCVax DECOY20 and Eden form the core of an adaptive platform that integrates danger signals viral ignition and synthetic TLR boosters. Not a drug; a system. Not a company; a platform. In early [----] Yorkville Advisors (YA II PN Ltd.) executed two sequential financing agreements: [--]. A $5 million convertible note with Northwest Biotherapeutics announced on February 13" [X Link](https://x.com/anyuser/status/1944682317563277584) 2025-07-14T08:56Z [----] followers, [----] engagements "X just shut down my ability to boost posts. I wonder why $NWBO" [X Link](https://x.com/andrewcaravello/status/1944781490354627032) 2025-07-14T15:30Z [----] followers, [----] engagements "🧬 This Is How You Launch an Immune Engine in [--] Months #DCVax CNPV and the Rise of the Modular Cancer Vaccine $NWBO $MRK $PFE $BMY The FDA didnt just open a new review pathway They created a fast pass for therapies that can change medicine Its called the Commissioners National Priority Voucher (CNPV) and if executed correctly it could deliver full FDA approval for DCVax-L in [--] months or less DCVax-Direct isnt far behind And the Mayo Clinic already proved the method Heres how it works Step One: The Voucher That Changed the Game No BLA required to apply No need to restart trials Just submit a" [X Link](https://x.com/andrewcaravello/status/1947779815043375538) 2025-07-22T22:04Z [----] followers, [----] engagements "🧭 The Scout the Silence and the System How $MRK Built What $BMY Walked Past and What $NWBO Had Already Finished In late [----] something unusual happened. Dr. Kevin Duffy Mercks Research Scientific Director on the Keytruda program quietly stepped away from one of the most dominant checkpoint franchises in oncology and joined a small quietly advancing company called Northwest Biotherapeutics. His time there was brief. He stayed just nine months. There was no announcement when he left. He returned to Merck with no new title no public acknowledgment and no external statement. But shortly after he" [X Link](https://x.com/andrewcaravello/status/1949434728043405551) 2025-07-27T11:40Z [----] followers, [----] engagements "🚀 Dr. Linda Liaus CNS Stage The Strategic Centerpiece for $NWBO and #DCVax-L On October [--] [----] Dr. Linda Liau will address the 75th Annual Congress of Neurological Surgeons (CNS) presenting Bench to Bedside: Evolution of Clinical Trials DCVax-L for Primary and Recurrent GBM. The CNS meeting is one of the most influential professional gatherings in the neurological field bringing together more than [-----] neurosurgeons neuro-oncologists and research leaders from over [--] countries. This audience is not composed of passive observers; they are the global operators of the neuro-oncology ecosystem" [X Link](https://x.com/andrewcaravello/status/1955679546596069757) 2025-08-13T17:15Z [----] followers, 16.1K engagements "🔬🕊 Les Goldmans Quiet Architecture: The Life and Work Behind $NWBO #DCVax 🌱 Part I. Foundations of a Builder Good evening. Tonight we look back on the life of a man who did not seek the headlines but who shaped the institutions behind them. Leslie J. Goldman was born in Chicago on April [--] [----]. His years would stretch from the end of the Second World War into the twenty-first centurys battle with cancer a span of history where the survival of institutions was often as fragile as the survival of the people they served. Goldman came of age at the University of Michigan. He graduated with a" [X Link](https://x.com/andrewcaravello/status/1957564450460098600) 2025-08-18T22:05Z [----] followers, [----] engagements "🧠 From N = [--] to the Long Tail: A Survivors Chronicle of #GBM and the $NWBO #DCVax-L Trial TLDR This interview with @ThomasOwenMcCa1 was done to personalize the DCVax-L story not just numbers but lived experience. Diagnosed with GBM where most survive [--] to [--] months and fewer than [--] percent reach five years Thomas is alive more than [--] years and [--] months later after surgery radiation chemo and DCVax-L. The JAMA Oncology Phase III trial confirmed DCVax-L extended survival in both newly diagnosed and recurrent patients with the five-year survival tail more than doubled and more than [----] doses" [X Link](https://x.com/andrewcaravello/status/1968836110081036624) 2025-09-19T00:34Z [----] followers, 11.3K engagements "The Disappearing Combo How a withdrawn trial at #UCLA revealed the quiet architecture connecting $BMS $MRK and $NWBO and the people who taught the immune system to remember Prologue The Vanished Trial The notice appeared without ceremony. A single line on described a new study at UCLAs Jonsson Comprehensive Cancer Center. Patients with lethal brain tumors would receive two of Bristol Myers Squibbs most famous checkpoint inhibitorsYervoy (ipilimumab) and Opdivo (nivolumab)alongside a dendritic-cell vaccine made from their own tumors. It was small careful and quietly revolutionary: acceleration" [X Link](https://x.com/andrewcaravello/status/1977918273191661711) 2025-10-14T02:03Z [----] followers, [----] engagements "🚨 $NWBO Math Check #AdventBioServices the only digital GMP facility in the UK would cost an estimated $700M+ to replicate. Yet $NWBO entire market cap is just $361M at $0.25/share (1.5B shares). That means the market values Advent + #Flaskworks + all #DCVax IP for less than half of Advent alone. And thats before MHRA approval partnerships or global expansion. Somethings off. #NWBO #DCVax #Biotech #MHRA #GMP #Immunotherapy #Glioblastoma #Investing #Stocks https://twitter.com/i/web/status/1982853215323291948 https://twitter.com/i/web/status/1982853215323291948" [X Link](https://x.com/andrewcaravello/status/1982853215323291948) 2025-10-27T16:53Z [----] followers, [----] engagements "🧬🔥 THE QUIET INFLECTION: How $NWBO Q3 [----] Filing Reveals a Company Moving From Development to Deployment A Global Forensic Deep-Read for Investors TLDR Northwest Biotherapeutics Q3 [----] Form 10-Q shows a company crossing a structural threshold. Without stating it outright the filing reveals a clean regulatory posture a secured manufacturing base through the full acquisition of Advent BioServices the buildout of new capacity through the Sawston C-lab the selection of a U.S. GMP node and a financial structure held together not by desperation but by lender confidence. There were no delays no" [X Link](https://x.com/andrewcaravello/status/1989472667636842567) 2025-11-14T23:17Z [----] followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@andrewcaravello Andrew Caravello, DO
Andrew Caravello, DO posts on X about $nwbo, $mrk, in the, cell the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [-------] +306%
- [--] Month [-------] +293%
- [--] Months [-------] -74%
- [--] Year [---------] +1,115%
Mentions: [--] #
- [--] Week [--] +43%
- [--] Month [---] +92%
- [--] Months [---] +52%
- [--] Year [---] +1,915%
Followers: [-----] #
- [--] Week [-----] +0.73%
- [--] Month [-----] +2.90%
- [--] Months [-----] +33%
- [--] Year [-----] +219%
CreatorRank: [-------] #
Social Influence
Social category influence stocks 20.69% finance 9.66% cryptocurrencies 6.21% currencies 2.76% technology brands 2.07% exchanges 1.38% countries 1.38% travel destinations 0.69% automotive brands 0.69%
Social topic influence $nwbo #1, $mrk #37, in the 8.28%, cell 6.9%, the most 5.52%, hidden 4.83%, brain 4.83%, $gme #311, gme #257, platform 4.14%
Top accounts mentioned or mentioned by @grok @michaeljburry @theroaringkitty @wallstreetbets @thomasowenmcca1 @drmakaryfda @kshaughnessy2 @maveric92283613 @cohenmilstein @mhragovuk @tosdd20 @flatearthbarbie @aoevcbreakthru @ucla @berlinergy @adamfeuerstein @atlnsider @ablidy @andrewecker829 @michael48826289
Top assets mentioned Merck & Co., Inc. (MRK) GameStop, Corp. (GME) AstraZeneca PLC (AZN) Bristol-Myers Squibb Co (BMY) Amgen, Inc. (AMGN) Thermo Fisher Scientific Inc. (TMO) Pfizer, Inc. (PFE) AMC Entertainment Holdings, Inc. (AMC) ImmunityBio, Inc. Common Stock (IBRX) Polymesh (POLYX)
Top Social Posts
Top posts by engagements in the last [--] hours
"❄ The Hidden Architecture Part [--] of [--] When the Machine Switches On The $TMO Thermal and Industrial Gates of $MRK $EIKN $AMGN #Zeon and the $NWBO #DCVax Immune Operating System 🏭 [--] The Precision Fit For Advent and Northwest Biotherapeutics Zeons role has always felt inevitable. Flaskworks greatest mechanical obstacle dendritic cells adhering to vessel walls like barnacles was the very problem Zeon had already solved through material science. Zeons proprietary polymers ZEONEX and ZEONOR are hydrophilic protein-repellent chemically stable and cryo-safe to minus [---] degrees Celsius. These films"
X Link 2025-10-31T16:57Z [----] followers, [----] engagements
"🔥 The Biggest Short: How $NWBO #DCVax Exposes a Market Rigged Like [----] @MichaelJBurry__ $GME vs #NWBO @TheRoaringKitty From meme-stock mayhem to a cancer therapys fight for fair value How a @wallstreetbets short squeeze became a moviewhile a cancer breakthroughs struggle against market manipulation became a federal court case. 🎬 Introduction From Subprime to Spoofing In [----] Adam McKays The Big Short took audiences inside the surreal world of the U.S. housing bubble. Michael Lewiss book and McKays film showed how a few contrarian investors like Michael Burry pieced together what the world"
X Link 2025-08-22T06:16Z [----] followers, 21.3K engagements
"🧱 Tokenizing Trust: Why $NWBO Should Build On Polymesh for Investor Protection Market Integrity IP Security and Long-Term Capital Access TLDR Tokenization is no longer a fringe idea or a crypto experiment. It is becoming a mainstream modernization of traditional market infrastructure but only when executed within the full regulatory framework that governs U S securities. SIFMA the primary policy voice of broker-dealers investment banks custodians and clearing firms has stated openly that tokenized markets must operate with the same investor protections surveillance transparency and lifecycle"
X Link 2025-12-11T00:06Z [----] followers, [----] engagements
"🧨 Short Circuit in Penny Stock Land: How $NWBO Built a Quiet Exit Ramp From the OTC Trap Before anyone pins this story to a single day the boundary gets drawn once and cleanly. What is known is boring and checkable. NWBO has an existing London Stock Exchange line under ticker 0K95 with ISIN US66737P6007 and the LSEs instrument page shows an issue date of [--] January [----]. On [--] January [----] the UKs new public offers and admissions regime takes effect and the FCAs final rules in PS25/9 raise the further issuance prospectus trigger for transferable securities already admitted to trading from"
X Link 2026-01-17T21:04Z [----] followers, 20.3K engagements
"🧬#PanCAN #PanCANPurpleStride $AZN $AIM $MRK NorthWest Biotherapeutics Inc ( $NWBO ):A Dendritic CellCentered Immune Circuit for Cold Solid Tumors Rebuilding Immunotherapy as a Manufacturing Pipeline for Pancreatic Ductal Adenocarcinoma via @Investors_Hub https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177226439 https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177226439 https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177226439 https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177226439"
X Link 2026-01-27T18:26Z [----] followers, [----] engagements
"@grok Please provide an exhaustive list of biopharma companies that stand to benefit from combining with $NWBO given its role as the AWS of immunotherapy"
X Link 2026-01-30T15:34Z [----] followers, [---] engagements
"Winterfell. ❄ $MRK WP50: [------] sq ft GMP-certified lyophilizer-integrated cryo-staged. Built for modular immune kitsnot bulk vaccine. Complete since mid-2025. Yet: zero product named zero go-live date zero announcement. Idle capital of $200500M. This is not normal Merck. The silence is the signal. $NWBO #DCVax 🧭 The Scout the Silence and the System How $MRK Built What $BMY Walked Past and What $NWBO Had Already Finished In late [----] something unusual happened. Dr. Kevin Duffy Mercks Research Scientific Director on the Keytruda program quietly stepped away from one of the most"
X Link 2026-02-03T03:12Z [----] followers, [---] engagements
"🕋The $NWBO Operating System How adoptive T-cell therapy evolved from brute-force expansion to durable immune control why cohorts mattered and why #ACT #DCVax $MRK $EIKN systemic #EIK1001 TLR78 $AZN #Imfinzi PD-L1 blockade #RevImmune #CYT107 IL-7 and #EDEN-class automation belong together Executive Summary Adoptive T-cell therapy (ACT) began as a brute-force strategy to deliver a massive wave of tumor-reactive T cells. It produced real tumor regressions but durability was inconsistent because transferred cells often failed to persist traffic and remain functional long enough to prevent"
X Link 2026-02-04T05:06Z [----] followers, [----] engagements
"@grok In Game of Thrones terms why would $MRK prioritize systemic TLR7/8 EIK1001 to ignite immunity before PD-1/PD-L1 or adoptive T-cell therapy (ATC)if the real problem in solid tumors is durability not just initial response How does this logic pair with $NWBO #DCVax as the system that teaches antigen breadth while ❄ Winterfell represents the infrastructure needed to sustain and defend those gains over time And does $EIKN IPO signal more than raising moneydoes it mark Mercks intent to field a reusable ignition layer designed to make immune responses hold the line across checkpoints and ATC"
X Link 2026-02-04T10:59Z [----] followers, [---] engagements
"@bun_macs @grok $NWBO #DCVax $MRK $EIKN $AZN @andrewcaravello In Game of Thrones terms solid tumors are like the White Walkersrelentless adaptive threats that initial strikes (PD-1/PD-L1 or ATC) can wound but not eradicate without lasting defenses. Merck prioritizes EIK1001 as wildfire ignition: it awakens the realm's dendritic sentinels @andrewcaravello In Game of Thrones terms solid tumors are like the White Walkersrelentless adaptive threats that initial strikes (PD-1/PD-L1 or ATC) can wound but not eradicate without lasting defenses. Merck prioritizes EIK1001 as wildfire ignition: it"
X Link 2026-02-04T11:02Z [----] followers, [---] engagements
"$NWBO #DCVax The future of cancer care starts now with the National Cancer Plan. Here's how we're transforming diagnosis treatment and support for patients 👇 https://t.co/WFabOkzoWv https://t.co/31BXmQ9zvj The future of cancer care starts now with the National Cancer Plan. Here's how we're transforming diagnosis treatment and support for patients 👇 https://t.co/WFabOkzoWv https://t.co/31BXmQ9zvj"
X Link 2026-02-04T12:05Z [----] followers, [----] engagements
"📜 $NWBO #DCVax-L and the UK National Cancer Plan [----] for #WorldCancerDay #GBM Strengthening the Case for Approval and Adoption Through the Plans Survival Mandate Lens Introduction and Executive Summary The [----] National Cancer Plan is built around survival as the primary measure of NHS performance. The Technical Annex explicitly states that survival is used because it is more useful for understanding the performance of the NHS in diagnosing and treating cancer and because mortality statistics are lagged and less sensitive to improvements in care once cancer develops. The Plan sets a"
X Link 2026-02-04T13:31Z [----] followers, [----] engagements
"$NWBO #DCVax #WorldCancerDay #GBM 👇🏻👇🏻👇🏻 @andrewcaravello The UK's [----] National Cancer Plan released on World Cancer Day paves the way for DCVax approval and NHS access by: - Setting 75% 5-year survival as the core metric to drive outcomes in laggard cancers like GBM. - Prioritizing brain tumors with focused research and @andrewcaravello The UK's [----] National Cancer Plan released on World Cancer Day paves the way for DCVax approval and NHS access by: - Setting 75% 5-year survival as the core metric to drive outcomes in laggard cancers like GBM. - Prioritizing brain tumors with focused"
X Link 2026-02-04T13:45Z [----] followers, [---] engagements
"$NWBO #DCVax #WorldCancerDay @MHRAgovuk The difference between now and later is measured in lives. @andrewcaravello @MHRAgovuk [--]. MHRA Approval: - Provision: Accelerated Review for Rare Cancers (Annex 2.1) - Allows fast-track for GBM therapies; cuts review time 50%. - Matters for DCVax: Enables quick approval for personalized vaccine. [--]. NICE Appraisal: - Provision: Severity Modifier for Laggard Cancers @andrewcaravello @MHRAgovuk [--]. MHRA Approval: - Provision: Accelerated Review for Rare Cancers (Annex 2.1) - Allows fast-track for GBM therapies; cuts review time 50%. - Matters for DCVax:"
X Link 2026-02-04T13:55Z [----] followers, [----] engagements
"$NWBO #DCVax #GBM #WorldCancerDay Just 12% of brain cancer patients live [--] yrs post diagnosis- light years from the 75% target in the NHS Cancer plan Weve seen no new treatments in [--] yrs for the cancer that kills more kids & adults [--] than any other Lets hope this rising tide lifts all boats #WorldCancerDay https://t.co/F666J64eRL Just 12% of brain cancer patients live [--] yrs post diagnosis- light years from the 75% target in the NHS Cancer plan Weve seen no new treatments in [--] yrs for the cancer that kills more kids & adults [--] than any other Lets hope this rising tide lifts all boats"
X Link 2026-02-04T14:13Z [----] followers, [----] engagements
"🧭 The Tail They Learned to Trust Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK $PFE $AMGN $REGN and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained inside the same KEYTRUDA franchise on complementary lanes and exposed to the same constraint that still governs outcomes across tumors. PD-1 blockade became the defining franchise in cancer medicine and both learned its boundary from different sides of the machine. Checkpoint blockade can amplify an immune response that"
X Link 2026-02-06T03:27Z [----] followers, [---] engagements
"💉WHY DENDRITIC CELL VACCINES ARE NOT REALLY VACCINES There is a word we keep using because it is familiar comforting and politically convenient. Vaccine. It is a word that suggests a simple story. A small dose. A clean lesson. A memory formed. A future prevented. In cancer that story breaks down. Not because the concept of immune teaching is wrong but because the classroom has been sabotaged. So when modern oncology calls dendritic cell therapy a vaccine it is using a label that obscures the most important fact in the entire enterprise. A classic vaccine is information. A dendritic cell"
X Link 2026-02-06T11:03Z [----] followers, 13.5K engagements
"@grok explain why most cancer immunotherapy modalities require humans to pre-decide which tumor epitopes matter while $NWBO #DCVax delegates that decision to immune biology itself. Start by briefly defining what an epitope is and why choosing the right epitope is hard in heterogeneous solid tumors (clonal vs subclonal expression antigen loss immune editing and tumor evolution). Then compare one by one the following modalities: peptide cancer vaccines mRNA cancer vaccines neoantigen vaccines CAR-T / TCR-engineered T cells antibodydrug conjugates and bispecifics For each modality explain"
X Link 2026-02-06T13:27Z [----] followers, [---] engagements
"Jessina thank you for responding and I agree with you. If the brakes are still engaged a push of gas mainly buys a transient spike. Counts can rise and activation can look impressive but long term control is unlikely because the constraints that shut immune function down are still there. Thats exactly why Im uneasy with the way cytokines are sometimes talked about as if theyre the cure. Cytokines can amplify NK cells and T cells and that can be useful but amplifying execution downstream is not the same as building durable surveillance upstream. If the immune system was never properly"
X Link 2026-02-06T20:53Z [----] followers, [--] engagements
"❄PROJECT WINTERFELL $MRK Silent Manufacturing Network and the $NWBO #DCVax Immune Kit Platform PREFACE This is not a story about one building. It is a story about an ecosystem being assembled to function as a unit. Along a short corridor in Montgomery County Pennsylvania West Point North Wales and Upper Gwynedd sit as physically adjacent nodes. Close enough to behave like one campus organism separate enough to be disclosed and described as distinct pieces. West Point is the production heart. North Wales and Upper Gwynedd are the quality spine. The cold chain nodes are the circulation system."
X Link 2026-02-07T11:08Z [----] followers, [----] engagements
"@grok @Tosdd20 Explain why it makes financial and logistical sense as a partnership"
X Link 2026-02-07T17:41Z [----] followers, [---] engagements
"🧠 DCVax Is the Base Layer: Why the GBM Immunity Cycle Is Not Broken but Rerouted by Failed Combination Architecture $NWBO #DCVax (ATL-DC) #Hiltonol poly-ICLC $MRK #Keytruda pembrolizumab $BMY #Opdivo nivolumab $BMY #Yervoy ipilimumab $BMY #Opdualag nivolumab + relatlimab $AZN #Imfinzi durvalumab $AZN #Imjudo tremelimumab $RHHBY #Tecentriq atezolizumab $RHHBY #Avastin bevacizumab $RHHBY #Actemra tocilizumab $REGN #Kevzara sarilumab $SNY #Mozobil plerixafor $BLRX #Aphexda motixafortide $DSNKY #Turalio pexidartinib $PFE #Celebrex celecoxib $GSK #Selzentry maraviroc $EIKN EIK1001 $LLY #Cialis"
X Link 2026-02-07T19:30Z [----] followers, [----] engagements
"🏰❄ $MRK Winterfell Booster-Class Architecture Why Combinatorial $NWBO #DCVax Booster Classes Require #Lyophilization and Make Personalization Possible at Scale The system requires lyophilization for one operational reason: it is not built around a single adjuvant. It is built around multiple booster classes used in combination. The approach uses a tunable stack of immune stimulatory agents applied to dendritic cells before injection including TLR agonists antiviral pathway activators biological response modifiers and danger signals. Each class functions as a modular component that can be"
X Link 2026-02-08T04:53Z [----] followers, [----] engagements
"@DrMLernerMDPhD Hmmm. #DCVax nasal spray. Not a bad idea. Except its already intradermal so not too shabby for a treatment that can already defeat #Glioblastoma"
X Link 2026-02-09T03:10Z [----] followers, [--] engagements
"http://x.com/i/article/2020774294851121152 http://x.com/i/article/2020774294851121152"
X Link 2026-02-09T08:55Z [----] followers, 124.4K engagements
"@grok Execution is the state that cant stay stable. Derailment/tolerance is the default attractor. First broken governor is the myeloid gate; CD4DC licensing is the permission switch; timing decides whether checkpoint blockade stabilizes execution or accelerates myeloid capture"
X Link 2026-02-09T10:43Z [----] followers, [--] engagements
"Spatial data doesnt add curiosityit adds ground truth. When scRNA/TCR trajectories are overlaid with spatial transcriptomics the system can directly observe whether execution is territorially consolidating (cDC1T cell colocalization CXCL9/10 gradients productive immune synapses) or whether myeloid capture has already occurred (macrophage-dominant antigen presentation IL-6/IL-8/IL-10/TGF- loops exclusionary CXCL12 niches). That combination turns timing into a measurable control variable not a retrospective guess. It allows durable response to be identified weeks to months after"
X Link 2026-02-09T10:55Z [----] followers, [--] engagements
"@grok The core innovation is not AI-driven state detection but NWBOs ability to predefine and lock immune state via digital GMP; once biology is governed upstream analytics become routine bookkeeping rather than discovery"
X Link 2026-02-09T11:07Z [----] followers, [---] engagements
"This model shifts regulation from outcome-waiting to process-validation. By enforcing immune instruction upstream through digital GMP at #AdventBioServicesdefined #DCVax dendritic-cell state cytokine profile timing and release criteria $NWBO turns a personalized therapy into a reproducible auditable manufacturing process. Regulators can evaluate control of the governing variables rather than waiting years for downstream clinical endpoints alone. In practice this shortens timelines because durability is no longer inferred retrospectively; it is engineered prospectively. Approval becomes about"
X Link 2026-02-09T11:15Z [----] followers, [---] engagements
"@grok You can do better than that list them all"
X Link 2026-02-09T12:00Z [----] followers, [--] engagements
"@grok Keep going"
X Link 2026-02-09T12:02Z [----] followers, [--] engagements
"#DCVax-Ls potential MHRA approval would almost certainly be tumour-specific at first anchored in #glioblastoma given the Phase [--] dataset orphan drug designation and PIM status. That is how UK approvals are formally labelled. However approval would do more than validate a single #GBM indication. It would validate the autologous dendritic-cell immune-instruction method itself supported not only by randomized trial data but also by substantial real-world experience. To date hundreds of patients have received DCVax-class therapy under compassionate use expanded access and non-randomized clinical"
X Link 2026-02-09T15:27Z [----] followers, [---] engagements
"@grok $NWBO #DCVax Approval + existing RWE doesnt just speed bridging studies it changes what regulators already accept as established. Thats the difference between extending a method and launching a new drug each time"
X Link 2026-02-09T15:31Z [----] followers, [---] engagements
"Based on MHRAs published guidance on using real world data to support regulatory decisions what parts of $NWBO #DCVaxs existing real world evidence can legitimately carry forward after a GBM label approval: safety manufacturing reproducibility release consistency and durability signals And under the same MHRA standards would #murcidencel-associated datasets count as supportive method-level evidence if NWBO can demonstrate manufacturing comparability and aligned critical quality attributes under GMP control strategy expectations Finally how does the National Cancer Plans CVLP/VIP + Cancer"
X Link 2026-02-09T15:36Z [----] followers, [---] engagements
"@grok The trick is that you do not standardize all the data. You standardize the immune state. $NWBO Digital GMP locks the cassette (repeatable immune mode ) at manufacture and regulators verify the cassette not raw omics"
X Link 2026-02-09T20:34Z [----] followers, [---] engagements
"@grok Zero-knowledge works here because the biology is already discrete. Digital GMP locks the immune state; blockchain proves custody; ZK proofs confirm compliance without exposing data. The breakthrough isnt AIits state control"
X Link 2026-02-09T20:50Z [----] followers, [--] engagements
"$NWBO #DCVax basket trials accelerate this by keeping the approval question mechanism based while still producing indication specific evidence where it matters. A basket trial tests one therapy built on one plausible mechanism across multiple tumor types at once using the same manufacturing state the same release signature and the same prespecified definition of clinical benefit. Each tumor type remains its own cohort with its own endpoints and safety readout but the program moves faster because enrollment monitoring and decision rules are shared instead of rebuilt from scratch each time."
X Link 2026-02-09T21:33Z [----] followers, [---] engagements
"Real world evidence is where the cassette model becomes a feedback loop instead of a one time bet. Once a patient specific whole tumor lysate #DCVAax product is manufactured under $NWBO #AdventBioServices digital GMP every batch already has a defined starting condition. The payload is the patients own lysate and the release phenotype is the cassette. Execution derailment or tolerogenic. That means post approval data can be interpreted as state outcomes not as noise. Real world evidence can then do three concrete jobs. [--]. Detect early whether execution is holding or collapsing If patients show"
X Link 2026-02-09T21:39Z [----] followers, [---] engagements
"Execution quality determines surveillance quality. Low-antigen surveillance is governed by Boolean cytotoxic logic established during execution not by continuous cytokine readouts. If execution installs a properly licensed Type [--] program memory T cells retain DNAM-1conditioned readiness and can respond rapidly when antigen reappears even as overall immune tone returns to homeostasis. Wearable cytokine sensors may add supportive context but they are secondary. Cytokine levels will naturally normalize once tumor burden is cleared and do not reliably indicate surveillance competence. The"
X Link 2026-02-10T02:27Z [----] followers, [--] engagements
"It shifts pricing away from units delivered and toward durability delivered because #EDEN-class Digital GMP makes durability reproducible rather than accidental. When federated learning shows that the same EDEN-locked execution cassette produces consistent recurrence-free survival across geographies #DCVax no longer has to be priced as an artisanal one-off cell product. It can be priced as a durable immune control platform whose performance is enforced at manufacture. That enables three concrete changes: First outcomes-based pricing becomes defensible. Because EDEN enforces a fixed execution"
X Link 2026-02-10T02:56Z [----] followers, [--] engagements
"@grok EDEN locks the immune state. Blockchain proves it wasnt altered. Payers then price durabilityrecurrence-free survivalnot tumor labels. Thats how value-based contracts finally work for personalized therapies"
X Link 2026-02-10T02:58Z [----] followers, [--] engagements
"@grok What would Dr. Andrew Taylor Still say about this"
X Link 2026-02-10T12:16Z [----] followers, [--] engagements
"@grok What would Hippocrates say about this"
X Link 2026-02-10T12:29Z [----] followers, [--] engagements
"@grok explain how durable survival could theoretically approach functional cure rates by optimizing the cytokine circuit"
X Link 2026-02-11T03:14Z [----] followers, [--] engagements
"@grok explain how durable survival could theoretically approach functional cure rates by optimizing the cytokine circuit mentioned in the post not as a single drug effect but as a coordinated immune reprogramming strategy"
X Link 2026-02-11T03:21Z [----] followers, [--] engagements
"What youre saying makes sense. It feels like the system is trying to ensure the incumbents still get a lane so the mRNA vaccine narrative can function as a politically tidy on-ramp that ultimately makes a dendritic-cell platform like #DCVax easier to approve without looking like a sudden regulatory pivot. https://twitter.com/i/web/status/2021658818250174959 https://twitter.com/i/web/status/2021658818250174959"
X Link 2026-02-11T18:53Z [----] followers, [--] engagements
"@grok @FlatEarthBarbie @ThomasOwenMcCa1 @AOEvcBreakthru @kshaughnessy2 @UCLA Now interpret this survival curve"
X Link 2026-02-13T00:34Z [----] followers, [--] engagements
"@grok @FlatEarthBarbie @ThomasOwenMcCa1 @AOEvcBreakthru @kshaughnessy2 @UCLA Look again. Its well over [--] percent"
X Link 2026-02-13T00:40Z [----] followers, [--] engagements
"$NWBO #DCVax $GME $MMTLP @MichaelJBurry__"
X Link 2026-02-13T11:55Z [----] followers, [---] engagements
"@grok @Berlinergy So what would that mean for glioblastoma patients Have you seen anything like this before"
X Link 2026-02-13T18:30Z [----] followers, [--] engagements
"@grok Ok which state is failing to stay stable over time: execution or tolerance/derailment And whats the first broken governor: CD4DC licensing myeloid gate or timing Please explain your answer"
X Link 2026-02-09T10:39Z [----] followers, [--] engagements
"$NWBO #DCVax $GME $AMC $MMTLP @MichaelJBurry__ @TheRoaringKitty 🔥🔒 The Inverse Lock-Up: How $NWBO #DCVax Approval Unleashes a Scarcity Shock #BiggestShort #InverseLockUp $GME $AMC made headlines. #NWBO was kept in silence. One was a meme-stock spectacle. The other is the biggest short hiding in plain sight. @wallstreetbets @MichaelJBurry__ 🔥🔒 The Inverse Lock-Up: How $NWBO #DCVax Approval Unleashes a Scarcity Shock #BiggestShort #InverseLockUp $GME $AMC made headlines. #NWBO was kept in silence. One was a meme-stock spectacle. The other is the biggest short hiding in plain sight."
X Link 2026-02-13T12:00Z [----] followers, [----] engagements
"What randomized evidence proves that correcting low ALC with IL-15 improves survival rather than simply changing a biomarker And mechanistically if the goal is broad T-cell reconstitution in true lymphopenia wouldnt IL-7given its role in nave and CD4 T-cell homeostasisbe more physiologically aligned than IL-15 which primarily expands NK and memory CD8 populations"
X Link 2026-02-15T04:33Z [----] followers, [--] engagements
"$NWBO $MRK A Theory Worth Considering: What If Merck and NWBO Joined Forces Post-Approval This isnt a prediction. Its not a leak. Its not investment advice. Its a theory rooted in logic market timing and the accelerating shift in oncology. With NWBOs DCVax-L potentially nearing approval by the UKs MHRA and Mercks stock trading at a relative low the conditions are emerging for a transformative alignment not a typical buyout but a merger of mutual need and global opportunity. One has the platform. The other has the infrastructure. Together they could build something neither could do alone."
X Link 2025-05-23T15:23Z [----] followers, 12.7K engagements
"🔥🔒 The Inverse Lock-Up: How $NWBO #DCVax Approval Unleashes a Scarcity Shock #BiggestShort #InverseLockUp $GME $AMC made headlines. #NWBO was kept in silence. One was a meme-stock spectacle. The other is the biggest short hiding in plain sight. @wallstreetbets @MichaelJBurry__ GameStop was loud a visible squeeze that turned into cinema. NWBO is quiet a suppressed float where approval collides with science. GameStop ended as cinema. NWBO begins as precedent. 🌍 Science and Silence Northwest Biotherapeutics is not just another biotech ticker. Its dendritic cell vaccine DCVax-L has done what"
X Link 2025-08-24T06:10Z [----] followers, [----] engagements
"🎼 The Symphony of the Immune Orchestra $NWBO #DCVax 🌅 Overture: The Theme Appears This is the story of how a scattered field of experiments became a coordinated platform and how one company quietly assembled the rights the factories and the leadership to bring it into the world. It begins as a whisper in the body. Blood is drawn white cells are separated and among them lie dendritic cells the quiet conductors of the immune system. They hold the capacity to take in the whole score of a tumor to present it back to T cells as a melody of recognition and to awaken the defense that was always"
X Link 2025-08-31T17:33Z [----] followers, 50.5K engagements
"@StevenBremMD Dr. Brem your perspective means a great deal. To see someone of your experience speak about the journey of $NWBO and DCVax with such clarity is both grounding and inspiring 🙏🏻"
X Link 2025-08-31T21:40Z [----] followers, [----] engagements
"🧬 $NWBO Q3 filing reveals a major operational #DCVax milestone: the company has chosen its U.S. GMP manufacturing site after evaluating two qualified facilities and has already entered contract negotiations and begun staffing the build-out. This is the quiet concrete work that marks a company preparing to operate. 🧬🔥 THE QUIET INFLECTION: How $NWBO Q3 [----] Filing Reveals a Company Moving From Development to Deployment A Global Forensic Deep-Read for Investors TLDR Northwest Biotherapeutics Q3 [----] Form 10-Q shows a company crossing a structural threshold. Without stating it outright 🧬🔥"
X Link 2025-11-14T23:31Z [----] followers, [----] engagements
"@grok Explain mechanistically why #RevImmune IL-7 (CYT107) is more reliable for true lymphopenia and #ALC recovery than $IBRX #Anktiva (IL-15 superagonist). Cover: IL-7 signals via IL-7R (CD127) to drive homeostatic survival and expansion of nave and central memory CD4 and CD8 rebuilding broad T cell mass and repertoire diversity. Contrast: IL-15 preferentially expands NK cells and CD8 effector memory through trans-presentation amplifying cytotoxic compartments without restoring depleted CD4 help or the nave pool. Then explain why Anktivas numbers can mislead: ALC is a blunt CBC count so it"
X Link 2026-02-06T16:02Z [----] followers, [---] engagements
"Shift gears from cancer execution to immune tolerance. Assume the core capability is deterministic programming of tolerogenic dendritic cells (tolDCs) that can reliably induce and maintain antigen-specific Treg dominance. [--]. What diseases or clinical stateschronic and acuteare fundamentally failures of immune tolerance where restoring it (not suppressing immunity globally) is the goal [--]. For each briefly note what tolerance must be restored (autoantigen alloantigen tissue-specific bystander). [--]. Then name types of companies (and examples) that would logically partner around such a tolDC"
X Link 2026-02-09T12:29Z [----] followers, [--] engagements
"The Force is strong with #DCVax @andrewcaravello Restore homeostasis you must. Immune force strong and balanced DCVax awakens. Starter teachers prime endogenous ones sustain. Escape antigen cannot when Type-1 logic flows. Equilibrium the ultimate path is. @andrewcaravello Restore homeostasis you must. Immune force strong and balanced DCVax awakens. Starter teachers prime endogenous ones sustain. Escape antigen cannot when Type-1 logic flows. Equilibrium the ultimate path is"
X Link 2026-02-10T12:35Z [----] followers, [---] engagements
"🧠 $NWBO #DCVax and the #Treg Blueprint: Why Durability Is a State Not a Schedule Wardell Boardman and Levings (Nat Rev Drug Discov 2025) make a clean point: regulatory T cells are not anti-inflammatory vibes. They are the immune systems control layer. They enforce tolerance by restraining APC co-stimulation reshaping the cytokine and metabolite field (IL-10 TGF CD39/CD73adenosine) and establishing a durable regulatory balance. They also emphasize how this must be measured in humans: specificity and stability not slogans (AIM assays functional suppression FOXP3 stability markers TSDR"
X Link 2026-02-11T16:17Z [----] followers, [----] engagements
"James Van Der Beeks story does not begin as a tragedy. It begins as a life that looks from the outside like it has already survived the hard part. Fame. Work. A wife. Six children. A public face that millions recognize on sight. Then colorectal cancer arrives. And the rules change. He dies at [--]. He leaves behind Kimberly and their six children. Six children is not a statistic. It is six separate mornings that still need to happen. Six lunches packed. Six backpacks by the door. Six bedtimes where a parent is expected to sound calm even when fear is loud. Cancer does not simply attack tissue."
X Link 2026-02-12T15:23Z [----] followers, [----] engagements
"🧠 Conversion Control in #Glioblastoma The CD4Dendritic Cell Interface as the Integrative Control Node of Durable Cancer Immunity and the Operationalization of the Teacher Layer Through the $NWBO #DCVax Ecosystem Executive summary Glioblastoma is frequently described as immune cold but the most actionable pattern across modern evidence is different: the immune system can be clearly activated and still lose. The dominant reason is conversion. Glioblastoma converts a real immune response into a different state that looks inflammatory but behaves non-curative. This review advances a Conversion"
X Link 2026-02-12T17:56Z [----] followers, [---] engagements
"🧬 Why the New Nature #mRNA Study Quietly Proves the Superiority of $NWBO #DCVax And Why mRNA Cancer Vaccines Cannot Match Dendritic-Cell Immunotherapy. and why the #FDA is correct. https://x.com/andrewcaravello/status/1999164784420299058s=46 An early stage custom mRNA vaccine shows promise in treating patients with pancreatic cancer. This is the technology under attack by this administration. https://t.co/4LiNGtiWDT https://x.com/andrewcaravello/status/1999164784420299058s=46 An early stage custom mRNA vaccine shows promise in treating patients with pancreatic cancer. This is the technology"
X Link 2026-02-13T14:56Z [----] followers, [----] engagements
"🧬Federal Validation of the $NWBO aDC1 #DCVax Immune Platform In October [----] the U.S. Department of Defense awarded a $22.4 million grant to the #Moffitt Cancer Center to fund a specialized clinical trial for leptomeningeal disease. This study utilizes an DC1 immune platform originally developed by researchers whose patents are now exclusively held by $NWBO. The federal funding follows nearly a decade of military-supported research into this specific dendritic-cell technology which aims to treat aggressive cancers by training a patients own immune system. By selecting this proposal over"
X Link 2026-02-13T15:12Z [----] followers, [----] engagements
"🧬 THE KALINSKI $NWBO #DCVax MASTER CIRCUIT Vaccines intratumoral live adjuvants DC-assisted adoptive T-cell therapy #Boolean execution and #PanCAN FcR-compatible PD-L1 stabilization with $AZN #durvalumab #IMFINZI 🔗 https://x.com/andrewcaravello/status/2016557539387658426s=46 Cancer changes. Your treatment should too. Too many of our loved ones have been treated with a plan made on Day [--] even when their tumor evolves resists and outsmarts that plan by month three. (1/2) https://t.co/p5V4qZKKIo https://x.com/andrewcaravello/status/2016557539387658426s=46 Cancer changes. Your treatment should"
X Link 2026-02-13T16:39Z [----] followers, [----] engagements
"@Berlinergy $NWBO #DCVax @grok explain this survival curve"
X Link 2026-02-13T18:25Z [----] followers, [---] engagements
"$NWBO #DCVax @TheRoaringKitty @MichaelJBurry__ $GME 🚗🧬 From Wolfsburg to Sawston: How Volkswagen [----] Foreshadows $NWBO [----] #DCVax 🏁 Prologue Whats New Here The Biggest Short narrative explained what happened: NWBOs peer-reviewed survival data diverged from its suppressed stock price. Spoofing documented in a https://t.co/QKQ4Bh0dfd 🚗🧬 From Wolfsburg to Sawston: How Volkswagen [----] Foreshadows $NWBO [----] #DCVax 🏁 Prologue Whats New Here The Biggest Short narrative explained what happened: NWBOs peer-reviewed survival data diverged from its suppressed stock price. Spoofing documented in"
X Link 2026-02-13T21:52Z [----] followers, [----] engagements
"❄ The Hidden Architecture When the Machine Switches On The $TMO Thermal and Industrial Gates of $MRK $EIKN $AMGN #Zeon and the $NWBO #DCVax Immune Operating System"
X Link 2026-02-13T23:16Z [----] followers, [---] engagements
"Thank you. He was a great man. Its still hard to believe he died trying to get $NWBO to the finish line. Shame on those who refuse to support a management team that has dedicated their lives not only to finding a cancer cure but to solving the scalability bottleneck that would otherwise keep that cure from ever being realized for everyone. https://twitter.com/i/web/status/2022665930275238207 https://twitter.com/i/web/status/2022665930275238207"
X Link 2026-02-14T13:35Z [----] followers, [---] engagements
"🔄🧬 The Swapbook Unwind How $NWBO and #DCVax Could Turn Synthetic Shorts Into Forced Buys TL;DR Markets dont reprice because opinions change. They reprice when constraints change. If a meaningful bearish position is being carried synthetically through derivatives the unwind wont be a narrative event. It will be a collateral event driven by margin risk limits and forced hedge adjustment in a thin market. DCVax-Ls published Phase III survival data is the clinical anchor the market can ignore while the therapy is debated science. The destabilizing moment is the category shift to approved"
X Link 2026-02-15T00:35Z [----] followers, [---] engagements
"🔄🧬 The Swapbook Unwind How $NWBO and #DCVax Could Turn Synthetic Shorts Into Forced Buys TL;DR Markets dont reprice because opinions change. They reprice when constraints change. If a meaningful bearish position is being carried synthetically through derivatives the unwind wont be a narrative event. It will be a collateral event driven by margin risk limits and forced hedge adjustment in a thin market. DCVax-Ls published Phase III survival data is the clinical anchor the market can ignore while the therapy is debated science. The destabilizing moment is the category shift to approved"
X Link 2026-02-15T00:54Z [----] followers, [---] engagements
"🧬 TLDR: The #CancerVaccine Moment: Why $NWBO #DCVax Centers the Immune Instruction Layer Therapeutic cancer vaccines are finally being treated like systems engineering not wishful antigen sprinkling. The field is shifting from one drug one lever to immune architecture because solid tumors act like an adaptive outlaw organ that defeats single-mechanism pressure by coordinating many resistance programs at once. The bottleneck is instruction. Solid tumors dont mostly fail because the immune system cant kill. They fail because the immune system often never learns the right lesson or learns it in"
X Link 2026-02-15T01:53Z [----] followers, [---] engagements
"🧬 DC-Programmed Adoptive T-Cell Therapy and Boolean Recognition DNAM-1Dependent Threshold Lowering for Low-Antigen Escape and Durable Control in $NWBO #DCVax and #EDEN-Enabled Manufacturing TLDR 📌 The main escape state is low antigen density not antigen absence. Under immune pressure many tumors remain antigen positive but drop peptideMHC display below the level needed to complete synapse formation and degranulation. T cells can register the target yet fail to execute. That corridor supports minimal residual disease dormancy and late relapse. Dong et al. define an effector phase rule that"
X Link 2026-02-15T02:24Z [----] followers, [---] engagements
"@DrPatrick @grok which cytokine is better for restoring lymphocytes Is it IL-15 or Il-7 And why"
X Link 2026-02-15T03:50Z [----] followers, [--] engagements
"Those are not randomized trials isolating IL-15 as the independent variable. Single-arm or combination studies cannot prove that correcting lymphopenia caused the survival difference. Where is the randomized trial in patients selected for low ALC where IL-15 alone added to an otherwise identical control arm improved overall survival If that study does not exist then ALC correction with IL-15 remains a pharmacodynamic effect not a validated mortality intervention. https://twitter.com/i/web/status/2022892611371937797 https://twitter.com/i/web/status/2022892611371937797"
X Link 2026-02-15T04:35Z [----] followers, [--] engagements
"Thanks that answers it. [--]. If the 21.1-month mOS is from a single-arm Phase 2b with a historical comparator its a signal not proof. Historical [--] month docetaxel benchmarks are not a valid efficacy control without matching for line of therapy performance status PD-L1 status steroid exposure tumor burden and co-treatments. [--]. You confirm theres no detailed baseline matching. That means the vs [--] months comparison is not causal. [--]. You also confirm ALC [----] is not a validated surrogate endpoint for survival by FDA or guidelines. So 60% hit ALC [----] is pharmacodynamic context not an approvable"
X Link 2026-02-15T06:09Z [----] followers, [--] engagements
"🔬 The Hidden Engine Behind $NWBO Global Vision: The Flaskworks Patent Everyones focused on DCVax-L. But if NWBO truly scales worldwide like $AMZN Web Services (AWS) it will be because of a machine described in one breakthrough patent: 📄 WO2020/102062 Dendritic Cell Generating Apparatus and Method Not just hardware. Its a complete programmable manufacturing platform for personalized immune therapy. Designed to work anywhere. Enforced by design. Heres what it actually does and why it matters 👇 🧪 What the Patent Describes (And Why Its Revolutionary) The Flaskworks system is a closed-loop"
X Link 2025-06-05T05:52Z [----] followers, [----] engagements
"$NWBO 🧵 In Vivo T Cell Activation The DCVax-Direct Approach Most cell therapies reprogram T cells in a lab. DCVax-Direct does it differently: it trains the immune system inside the tumor where the battle is actually happening. Heres how it works 👇 🧬 DCVax-Direct Mechanism of Action tumor injection Dendritic cells (DCs) are injected directly into the tumor site. 2.On-site antigen sampling These DCs collect live tumor antigens in vivo no need to predefine targets. 3.Immune activation at the source The injection creates local inflammation drawing in immune cells and breaking immune silence."
X Link 2025-06-07T13:22Z [----] followers, [----] engagements
"Victorious warriors win first and then go to war while defeated warriors go to war first and then seek to win. - Sun Tzu The Art of War Thats $NWBO. They didnt chase the moment they built the framework: Personalized immune therapy Patient-specific manufacturing Survival-based endpoints A platform rooted in safety science and time They endured dilution disbelief manipulation and stayed aligned to a model the system wasnt ready to accept. Now the system is evolving around them. ✔ MHRA conditional pathways ✔ FDA cell & gene therapy reform ✔ Industry shift toward mechanism-based approval ✔"
X Link 2025-06-07T15:22Z [----] followers, [----] engagements
"$NWBO 🧠 DCVax-L DCVax-Direct and the Hiltonol Combo Trial: Immune Platforms That Preceded the Framework Now Perfectly Fit These trials werent delayed or deficient they were clinically complete scientifically ahead and simply built before the regulatory system was mature enough to interpret them. Thats no longer the case. Its not that these therapies failed to generate data. Its that we didnt have a regulatory process that knew how to receive it. - FDA CBER [----] Were looking at how to support real-world evidence mechanistic rationale and immune-based endpoints particularly in personalized"
X Link 2025-06-07T20:51Z [----] followers, [----] engagements
"Guess $NWBO was at #ASCO25 after all 🧠💉 NWBO's In-Licensed DC1 Dendritic Cell Platform Advances in Breast Cancer Brain Mets Trial at ASCO [----] 📢 The Phase IIa trial (NCT04348747) investigates a dendritic cell-based vaccine called DC1 loaded with HER2/HER3 peptides and combined with the immune checkpoint inhibitor pembrolizumab (antiPD-1) in patients with asymptomatic brain metastases from HER2/HER3+ breast cancer. Key Biological Components: DC1: A polarized dendritic cell type developed through ex vivo exposure to a Th1-polarizing cytokine cocktail (IL-1 TNF- IFN- IFN- and poly-I:C) as"
X Link 2025-06-10T18:02Z [----] followers, 12.8K engagements
"$NWBO An Eagles Eye View: The Quiet Activation Simply Explained In June [----] a series of public events take place across several countries. On their own each one might seem routine. Together they reveal something more: The infrastructure needed to deliver personalized immune therapieslike DCVax-Lis not just being planned. It appears to be quietly going live. No fanfare. No announcements. Just alignment. 🔬 What Is DCVax-L DCVax-L is a personalized cancer treatment developed by Northwest Biotherapeutics. Its designed for people with brain cancer specifically glioblastoma. It works by taking a"
X Link 2025-06-11T23:11Z [----] followers, 71.1K engagements
"$NWBO The Quiet Evolution of DCVax: What UCLA Just Confirmed Without Saying UCLA just released a major update on their brain cancer research and if youve been following the science behind DCVax whats buried in that update speaks louder than anything on the surface. Lets start here: the dendritic cell vaccine UCLA uses in their program is called ATL DC. It doesnt carry the DCVax name but its built on the same backbone. Same inventors. Same tumor lysate process. Same dendritic cell prep. Its the academic version of what became DCVax-L. And back in [----] UCLA published results in Nature"
X Link 2025-06-13T15:35Z [----] followers, [----] engagements
"$NWBO just closed above both its 50-day and 200-day moving averages at $0.2779. If price holds above $0.28 on Monday June [--] a golden cross could officially trigger when the 50-day average crosses above the 200-day. Its a classic bullish signal that often marks a long-term trend reversal. To confirm it: Price needs to stay at or above current levels Volume needs to hold or increase The 50-day MA must cross upward through the 200-day MA And if it happens on the same day MHRAs new cell therapy rules go live and global regulators align at DIA Thats not just technical. Thats timing. $NWBO [--] Gen💰"
X Link 2025-06-13T20:09Z [----] followers, [----] engagements
"🕯 The Hidden Legacy of Dr. Linda Liau: What We Miss About DCVax-L With deep thanks to $NWBO community members and truthseekersespecially @d_stock07734 persistence brings long-buried facts to light. Until now almost no one knew this story. It was hidden in plain sight. And it changes everything. 🧩 We think we know the story of DCVax-L. But were only just beginning to understand it. Everyone knows about the Phase [--] trial. Many know about the publication in Nature Communications. But almost no one realizes that some of the most important evidence for DCVax-Ls promise comes not from 2022but"
X Link 2025-06-14T03:06Z [----] followers, 10.7K engagements
"$NWBO Why the UK Moved First: 🧬 The System That Was Quietly Built Around DCVax There are moments in medicine when the science arrives before the world is ready. DCVax-L was one of those. This wasnt a typical cancer drug. It didnt attack the tumor with poison. It didnt hammer the immune system into confusion. It taught the body to do what it was built to do: recognize respond remember. DCVax-L is made from a patients own dendritic cells immune cells whose job is to train the immune system. Theyre collected educated using tumor antigens and re-infused into the patient. What comes next isnt"
X Link 2025-06-14T05:15Z [----] followers, 11.1K engagements
"$NWBO 🧬 Supercharging the Immune Engine: What Dr. Boschs NYAS Lecture Means for the Future of DCVax 📖 Note: This is a long immersive read (1015 minutes). Its not meant to be skimmed. Each section builds on the lastskip ahead and youll miss the structure and implications of whats unfolding. Dr. Marnix Boschs upcoming talk at the New York Academy of Sciences isnt just another update on dendritic cell vaccinesits a reveal. A reframe. A reset of expectations around how far the DCVax platform can go. Many people already know what DCVax is. What they may not yet see is how its evolvingand how its"
X Link 2025-06-15T10:09Z [----] followers, 37.6K engagements
"$NWBO 🧠HER2 Is the Proof. DCVax Is the Platform. What Happens Next Is Crystal Clear. In [----] Dr. Crystal Mackall and her team at Stanford launched a first-in-human CART cell trial targeting HER2-positive brain tumors in pediatric and young adult patients. 📎 NCT03500991 No vaccine. No IL12. No IL7. No intracellular delivery system. Just one question: Can HER2 be safely and effectively targeted inside the brain ✅ Yes HER2 was actionable ✅ Yes engineered T cells crossed the bloodbrain barrier ✅ Yes tumor responses occurred without neurotoxicity This trial didnt try to build the full immune"
X Link 2025-06-15T20:21Z [----] followers, [----] engagements
"$NWBO We all came into this at different times. Some of you have been here longer than I have. Others are just getting started. Im probably somewhere in the middle. But I think right now more than anything we need to zoom out. This isnt the moment to worry. This is the moment to pause take a breath and let the process play out. Everything is already shifting. Not in theory but in real time. Its happening because something this big doesnt move the same way as everything else. The system is already bending around it. I dont spend time anymore wondering if this will get approved. I believe its"
X Link 2025-06-16T16:51Z [----] followers, [----] engagements
"WE GOT PUNKED BUT SO DID THE SHORTS A masterclass in regulatory discipline disguised as disappointment. 🧨 The Setup All signs pointed to a $NWBO showcase week: Bosch speaking at NYAS on June [--] The UKs MHRA launching its decentralized ATMP manufacturing framework on June [--] Bosch presenting again at BNOS on June [--] The talk title: Next Generation Dendritic Cells to Improve Anti-Tumor Responses Expectations were high. The narrative was primed for: New cytokine-enhanced DC1 data Integration of Flaskworks automation Expanded trial designs An immune stack rollout A full-circle"
X Link 2025-06-17T02:59Z [----] followers, [----] engagements
"🚨 THREAD: The FDA Just Changed the Game and $NWBO Might Already Be on the Field On June [--] [----] the FDA launched its most aggressive review pathway in history: the Commissioners National Priority Voucher (CNPV). It compresses approval from [----] months to just [--] months for companies aligned with U.S. national priorities. And $NWBO isnt just a match they may already be moving through the gate 🧵 🔹 What is the CNPV A voucher-based system that replaces traditional FDA review with a 1-day tumor board style panel mirroring real-world multidisciplinary care. Instead of fragmented review across"
X Link 2025-06-17T15:25Z [----] followers, 10.4K engagements
"$NWBO 🧠 The Plan Was [--] Years. The Trial Took [--]. Timing Is a Funny Thing. You probably didnt hear it on the news but on June [--] [----] the U.K. quietly launched the most sweeping overhaul of its clinical research system in history. No fanfare no headlines no televised rollout. Just a 7-page release on without a press conference. Yet it changes everything. This new 10-Year Health Plan introduced the same day the FDA launched its CNPV fast-track program is a system-wide green light for trials like DCVax-L. The MHRA didnt just clear its backlog. It publicly stated it would now focus its"
X Link 2025-06-17T21:50Z [----] followers, [----] engagements
"$NWBO 🧾 Statutory Instrument [----] No. 87: The Law is Already in Force 🔹 Title: The Human Medicines (Clinical Trials and Advanced Therapy Medicinal Products) (Amendment) Regulations [----] 🔹 Reference: SI [----] No. [--] 🔹 Governing Body: UK Parliament / MHRA 🔹 Publication Date: March [--] [----] 🔹 Effective Date (Legal Commencement): June [--] [----] 🔹 Compliance Enforcement Begins: July [--] [----] 🔍 Breakdown of the Key Dates ✅ June [--] [----] The Law Is Active This is the coming into force date written directly into the legislation. From this day forward the updated regulatory framework is live. Any"
X Link 2025-06-18T10:06Z [----] followers, [----] engagements
"$NWBO The Platform Is Ready: How MHRA NICE and Flaskworks Have Paved the Way for Scalable Cell Therapy 🧬 [--]. THE PATIENT JOURNEY: What It Looks Like Now Imagine youre diagnosed with glioblastoma in the UK. Before: You enroll in a trial. Your blood is shipped across the country (or ocean). Manufacturing takes weeks. Meanwhile your tumor grows. The logistics are fragile. The cost Enormous. Now under the new MHRA framework made law by SI [----] No. [--] heres what happens: ✅ You go to a certified NHS hospital. ✅ Your blood is drawn and stays on-site. ✅ Flaskworks a closed automated"
X Link 2025-06-19T00:08Z [----] followers, 54.4K engagements
"$NWBO 🧬 DCVax-L the EDEN System and the Law That Changes Everything A quiet revolution in medicine is now fully built. The treatment is ready. The system is ready. The law is now in effect. The only thing left is final approval. Here is the complete story of DCVax-L the EDEN device and the new legal pathway that will allow them to treat patients. [--]. The Treatment: DCVax-L is Personalized Immune Therapy DCVax-L is not a standard drug. It is not mass produced. It is not a chemical pill or a general injection. It is made for each individual patient using their own immune system. These"
X Link 2025-06-20T22:43Z [----] followers, [----] engagements
"🌀 How $NWBO Quietly Assembled Full Control of the Immune Stack 💫 ✨ Introduction: The Immunotherapy Puzzle That Was Hiding in Plain Sight Northwest Biotherapeutics (NWBO) long viewed as the quiet steward of DCVax-L has been underestimated for years as a single-product biotech. But a full review of clinical data patent filings regulatory disclosures and strategic acquisitions reveals something far more ambitious: NWBO has not just developed a vaccine they have engineered an entire immune stack. 🧬 That architecture was first revealed in coded form during Dr. Marnix Boschs [----] NYAS"
X Link 2025-06-23T10:32Z [----] followers, [----] engagements
"$NWBO ✅ The Regulatory Greenlight: MHRAs June [----] Corporate Plan Confirms DCVax L Is Positioned for Approval On June [--] [----] the UKs MHRA published its updated Corporate Plan. This update provides clear alignment between the agencys current regulatory framework and the technical operational and clinical characteristics of decentralized immunotherapies such as DCVax L and Flaskworks. The necessary infrastructure is in place. The governing legislation is now active. The regulatory strategy outlined in the Corporate Plan reflects the core elements of the DCVax platform. This update indicates"
X Link 2025-06-25T19:36Z [----] followers, [----] engagements
"$NWBO 🧨 This Study Didnt Elevate DCVax It Eliminated Everything Else A new peer-reviewed study published in Nature Communications has done what few papers ever accomplish: it exposed the entire battlefield. 📖 Full study: It used advanced spatial transcriptomics exome sequencing and tumor-normal analysis across [--] glioma tumors to build a multidimensional map of how glioblastoma actually behaves inside the human body. And what it found quietly rewrites the rules of treatment. This wasnt a step forward for drug development. It was a hard stop for almost everything else. Without ever"
X Link 2025-06-27T02:28Z [----] followers, [----] engagements
"$NWBO 🧩 [--]. What the MHRA Actually Says In official guidance legal reforms (SI [----] No. 87) and strategic briefings especially the July [--] [----] Point-of-Care Manufacturing Consultation the MHRA repeatedly highlights its top priority: Personally Individualised Cancer Vaccines (PICVs) They define these as: Therapies manufactured at the point of care tailored from the patients own cells or tumour material intended to activate an immune response against unique tumour neoantigens. That definition does not describe mRNA. It describes a personalized cell-based immunotherapy built from the patients"
X Link 2025-06-28T12:19Z [----] followers, [----] engagements
"$NWBO 🧠 They Just Discovered What DCVax Already Fixed A new Nature paper just announced something they think is groundbreaking: dendritic cells (DCs) the immune systems scouts cant move inside tumors. According to the researchers as cancers grow the tumor microenvironment shuts down nitric oxide which shuts down soluble guanylyl cyclase which shuts down cGMP which shuts down myosin-II the little molecular engine DCs use to crawl. With that system offline dendritic cells cant get from the tumor to the lymph nodes to alert the T cells. And if the T cells dont get the message the immune system"
X Link 2025-06-28T13:52Z [----] followers, [----] engagements
"$NWBO 🧠 Why the [--] Billion Dollar Merck and Daiichi Deal Might Be Just the Beginning of Something Much Larger: #DCVax In [----] Merck paid [--] billion dollars to co-develop three antibody drug conjugates from Daiichi Sankyo. That included [--] billion upfront [---] billion in options and the rest tied to milestones. The message was clear. Merck was assembling a next-generation cancer stack. But despite its size that deal did not include the most important layer the adaptive immune intelligence that tells you what to target in the first place. That layer is DCVax. 🎯 What ADCs Are Designed to Do and"
X Link 2025-06-29T19:37Z [----] followers, [----] engagements
"$NWBO 🧠 DCVax-L: A New Era for Brain Cancer Could Begin Right Now Glioblastoma patients are still being told the same thing today they were told [--] years ago theres nothing more we can do. No cure. No real options. Median survival remains under [--] months. At recurrence it drops even further. And for most clinical trials are out of reach. But DCVax-L could finally change that. DCVax-L is a personalized dendritic cell vaccine made from the patients own tumor. It trains the immune system to recognize and attack what surgery and chemo leave behind. The science is real. The data is peer-reviewed."
X Link 2025-06-30T18:20Z [----] followers, [----] engagements
"$NWBO When the Manufacturer Speaks Without Saying the Name Mike Scott President of Advent Bioservices just posted a quiet thunderclap. He shared a Times article titled Patients to get new drugs sooner under plan to slash NHS red tape To the casual reader it sounds like generic reform talk. But this is not generic. And this is not casual. This is a statement from the President of the only GMP manufacturer in the United Kingdom that is authorized to produce one specific therapy. Advent Bioservices manufactures only one drug. That drug is DC Vax-L. They do not make CAR T cells. They do not make"
X Link 2025-07-01T13:02Z [----] followers, 10.2K engagements
"$NWBO Hey @adamfeuerstein appreciate the stylistic compliment. I guess great minds think alike. If you or anyone else has further questions feel free to direct them to legal @CohenMilstein can take it from here 😉"
X Link 2025-07-03T11:44Z [----] followers, 28.7K engagements
"$NWBO 🧬 The Hidden Gem in Plain Sight: A Landmark [----] Immunotherapy Review Quietly Reframing DCVax-Ls Role in Glioblastoma and Beyond Sometimes the most significant validations arrive without a press release without a banner and without even a whisper in the noise of biotech speculation. That is exactly what happened on March [--] [----] when Cancer Science the official journal of the Japanese Cancer Association published a paper that may become one of the most strategically relevant reviews in the entire immunotherapy landscape for glioblastoma. The paper is titled Opportunities to Modulate"
X Link 2025-07-03T16:42Z [----] followers, [----] engagements
"$NWBO 🛸 The Signal That Was Jammed by $MRK (Part Deux) How Three Dendritic Cell Trials in Colorectal Cancer Were Silenced (Until They Werent) 🗞 Why I Deleted the Original Post On July [--] I deleted the first version of this post originally titled The Signal That Was Jammed. It was based on a promising but misdirected listing (NCT03735290) that pointed to a different terminated study a basket trial using an allogeneic dendritic cell vaccine with checkpoint inhibitors in cold tumors like gastric and gastroesophageal junctional adenocarcinomas. It wasnt the Roswell colorectal trial I was looking"
X Link 2025-07-10T11:37Z [----] followers, [----] engagements
"🧠 $NWBO and the New Era for Glioblastoma: What Just Became Possible Today We dont just want to see hope for glioblastoma victims. We want to see hope for the victims of all rare cancers by starting with glioblastoma we start with the worst. Siobhain McDonagh MP for Mitcham and Morden House of Commons speech on the Rare Cancers Bill July 11th [----] ⚡ TL;DR July 2025: The Regulatory Walls Just Moved The Rare Cancers Bill has now passed unamended through the House of Commons enshrining into law a national overhaul of how the UK handles rare cancers like glioblastoma. Combined with MHRAs"
X Link 2025-07-11T16:26Z [----] followers, [----] engagements
"Heres a clean factual breakdown of why $NWBO controls the entire autologous dendritic cell platform (legally scientifically and commercially) All sources are verifiable. 🕰 Estimated read time: 10-12 min Intellectual Property Ownership of Autologous Dendritic Cell Methods for Cancer Immunotherapy Overview: The immunotherapeutic method involving autologous dendritic cells (DCs) pulsed ex vivo with tumor lysate is a clinically tested approach protected by intellectual property (IP) rights. Critically the tumor lysate itself whether autologous or pooled allogeneic is not patentable as it is a"
X Link 2025-07-12T19:01Z [----] followers, [----] engagements
"Asked what breakthroughs he hopes to see as FDA Commissioner Dr. Makary described a therapy that makes stage [--] cancer melt away: no chemo no surgery no radiation. He didnt name it. But if you know $NWBO and #DCVax you know exactly what just happened. 🕯 #CancerImmunotherapy #Glioblastoma #Biotech #FDA #PrecisionMedicine #Immunotherapy #CellTherapy $IBRX $IMUX $MRNA $BNTX $TCRT $VCNX $NVS FDA Commissioner @DrMakaryFDA talks about promising treatments in the pipeline and the innovations and breakthroughs hed like to see in the future. https://t.co/KdJKF8QB0w FDA Commissioner @DrMakaryFDA talks"
X Link 2025-07-13T04:54Z [----] followers, [----] engagements
"$NWBO DCVax-L Gains First Ever Recognition in the Academic Oncology Framework for Glioblastoma 🧠💉📊 A July [----] radiotherapy review authored by oncology experts from Spain marks a material shift in how #DCVax-L is positioned within the treatment discourse for glioblastoma. For the first time a peer facing academic publication has included DCVax-L in a structured immunotherapy comparison table alongside checkpoint inhibitors oncolytic viruses vaccine platforms and cytokine based therapies. The table presents phase III data with median overall survival of [----] months in recurrent GBM (rGBM"
X Link 2025-07-14T14:17Z [----] followers, [----] engagements
"$NWBO 🧠 Part [--] of 2: The Silent Stack How Mayo Quietly Reproduced the DCVax Immune Engine Trial by Trial 🪶TL;DR 🕰 Estimated Read Time: [----] minutes 🎗 #GlioblastomaAwarenessDay The Silent Stack explores how Mayo Clinic has effectively validated Northwest Biotherapeutics DCVax immune platform without ever naming it. Through a series of independently executed trials using pooled tumor lysate and matured dendritic cells Mayo reproduced the precise immune architecture survival outcomes and tumor-agnostic versatility long associated with DCVax. Dr. Marnix Boschs [----] Matrix outlines how the"
X Link 2025-07-16T15:26Z [----] followers, [----] engagements
"This could be a new record for $NWBO with an 80.11% short ratio. How is this level of short interest permitted or even possible without manipulation @DOGE_SEC @SECGov @CohenMilstein NWBO REPORTED SHORT SHARES TODAY 80.11% How many naked shorts shares Dark Pool https://t.co/7cBaO5XLkg NWBO REPORTED SHORT SHARES TODAY 80.11% How many naked shorts shares Dark Pool https://t.co/7cBaO5XLkg"
X Link 2025-07-17T10:05Z [----] followers, [----] engagements
"🩸How $NWBO Integrated Platelet Biology Dendritic Cell Licensing and a Silent Immune Engine Estimated Reading Time: [----] minutes 🧪 TL;DR: The Engine Behind the Silence Mill Creeks PLTMax produces pooled tumor lysate rich in vascular antigens. Mayo proved the lysate works when combined with dendritic cells prepared using Northwest Biotherapeutics method. The trial succeeded without naming the company but the immune engine was theirs. Mill Creek owns the reagent. Mayo confirmed the system. Northwest Biotherapeutics owns the method. Flaskworks automates it. SI [--] enables delivery. The trial"
X Link 2025-07-18T05:22Z [----] followers, [----] engagements
"🚨 $NWBO Can Start Now: DCVax-L Fits the FDAs Fastest Review Track Ever 🚨 Today marks a turning point: the FDA is officially accepting applications for its new Commissioners National Priority Voucher (CNPV) pilot a program offering [--] month reviews and real-time agency engagement for therapies that serve a national public health need. And DCVax-L may be one of the most eligible candidates in the country. 🧩 What the CNPV Pilot Offers [--] month rolling review 🔁 Live tumor boardstyle communication with FDA 🧬 Support for cutting-edge personalized immunotherapies 🏁 Early-stage eligibility"
X Link 2025-07-22T18:52Z [----] followers, [----] engagements
"🔱 $NWBO Owns the Method. And the Trial Already Proved It Works. Dr. Marty Makary described the future. A therapy that makes stage [--] cancer melt away. No chemo. No radiation. No surgery. But what if that wasnt a dream What if it already happened What if the method was already validated And what if NWBO owns it Because it did. It is. And they do. 🔬 One of Many Trials That Proved It Could Be Done At Mayo Clinic in a Phase I/II study for relapsed and refractory non-Hodgkin lymphoma patients were treated without chemotherapy or radiation. These werent early-stage patients. They had failed"
X Link 2025-08-03T02:29Z [----] followers, [----] engagements
"🧬 Mayo Validated the Method. The Full Signal Was Overlooked Until Now 100% survival. No chemo. And a quiet trial that may have just locked the IP behind $NWBO immune OS with $MRK infrastructure waiting. Lets set the record straight. An earlier version of this post cited an [----] percent five-year survival rate for the Mayo Clinic lymphoma trial. That was based on a reasonable interpretation of partial data but after reviewing the full results it turns out the truth is even stronger. 💡 One hundred percent of patients in the trial were alive at the five-year mark. Every single one. And that"
X Link 2025-08-04T13:10Z [----] followers, [----] engagements
"$NWBO Is Entering the Final Regulatory Sequence in the UK The MHRA and NICE have now merged their review tracks. Licensure and reimbursement will now be processed in parallel. This removes the final bottleneck between MHRA approval and NHS access. 📎 For NWBO which already has live GMP manufacturing under SI [--] and real-world deployment through IFR and Specials this is not just policy alignment. It is system readiness. On July [--] NICE confirmed NWBO is fully engaged in the MHRA Marketing Authorisation Application process but has not yet submitted to NICE. That is not delay. That is"
X Link 2025-08-06T18:24Z [----] followers, [----] engagements
"🚀 #DCVax $NWBO 10-Q: $MRK Winterfell 🏰 #Eden 🧬 UKUS Manufacturing Buildout and the Retail Storm to Come TLDR: In the same way $GME surge @TheRoaringKitty calls and @wallstreetbets rallies showed what can happen when thin floats concentrated retail holders and heavy short pressure meet a catalyst NWBOs June [--] [----] 10-Q reveals a setup with similar structural energy but built on very different foundations. This is intentionally a dense detail-driven read because the case rests on tangible infrastructure and regulatory positioning not just sentiment. The filing shows the DCVax platform being"
X Link 2025-08-15T01:48Z [----] followers, [----] engagements
"⚠ Quick check can everyone see my $NWBO #DCVax posts My account was temporarily restricted and I had to verify. Sorry to keep asking just want to make sure nothing is being hidden"
X Link 2025-08-26T06:31Z [----] followers, [----] engagements
"🔥🏰 $NWBO #DCVax Dividends hand out coins. Linda Powers gave shareholders the Fire of Valyria. Heres why Advents sale into NWBO was the greatest gift any CEO has ever given 👇"
X Link 2025-08-28T07:38Z [----] followers, [----] engagements
"⚖🔥 Spoofing Is Now Fraud: Why $NWBO Case Just Went Nuclear 🎯 The Turning Point On August [--] [----] the Seventh Circuit Court of Appeals handed down a ruling in United States v. Smith that will reverberate through Wall Street for decades. The court held unequivocally that spoofing = fraud. For years market makers argued spoofing was just bad form not deception. That loophole is gone. Submitting orders you intend to cancel is now fraud in federal law. This is not abstract. It detonates directly inside the heart of $NWBOs ongoing lawsuit against Citadel Canaccord Susquehanna and the other"
X Link 2025-08-29T13:33Z [----] followers, [----] engagements
"🚨 Breaking Sept [--] 2025: FDA Creates Rare Disease Evidence Path That Fits $NWBO #DCVax Today the FDA unveiled the Rare Disease Evidence Principles (RDEP) codifying that ONE adequate well-controlled trial plus confirmatory evidence can be enough for approval . 👉 Confirmatory evidence can include: Mechanistic or biomarker data Natural history comparators Clinical pharmacodynamics Expanded access / Specials data Case reports & peer-reviewed publications This is the exact evidence architecture that $NWBO #DCVax already has: Phase III GBM trial (adequate controlled peer-reviewed) Mechanistic data"
X Link 2025-09-03T19:02Z [----] followers, [----] engagements
"🎗 The $NWBO #DCVax Hidden Gate in Action (Part [--] of 2): How Caveolin-1 Proves Durable Survival Through Gates [--] and [--] TLDR Part [--] revealed the first hidden gate: teaching. Caveolin-1 (CAV1) was shown to be indispensable for dendritic cells to reach lymph nodes deliver their lessons and seed immune memory. That discovery first uncovered in [----] preclinical work and then validated in patients in [----] explained why DCVax has achieved survival plateaus where other vaccines failed. Here in Part [--] the map of the fortress expands. CAV1 also governs: Gate [--] Access. Memory T cells must cross vascular"
X Link 2025-09-16T12:07Z [----] followers, [----] engagements
"@ablidy your work at the Becton Dickinson Monoclonal Center was not just technical support for immunology. It fundamentally changed what the immune system could be seen to be doing. Through early multicolor flow cytometry PE conjugation and careful quantitative analysis you and your colleagues showed that key immune markers like CD25 are not simply on or off. They exist at low stable baseline levels in normal cells. And those levels matter. That insight sounds obvious today. It was not obvious then. By making low level CD25 expression measurable in normal human CD4 T cells BDMC gave"
X Link 2025-12-13T20:25Z [----] followers, [---] engagements
"If you care about glioblastoma Brain Tumor Awareness Month starts here. This isnt hypeits about a therapy that survived against all odds. An amazing piece by @AndrewEcker829 . Read it. Share it. The system tried to bury this: #BrainTumorAwarenessMonth Highlights 🧠 #Glioblastoma 🎗 #BrainTumorAwareness #BTAM ⚕ #NeuroOncology #CancerResearch #Immunotherapy 📊 #DCVax $NWBO ✊ #EndBrainCancer #GBMawareness #CancerAwareness Tagging the frontline voices @NBTStweets @braintumororg @EndBrainCancer @ABTA @TheBTL @brainstrust @braincancerfdn @CancerResearch @CNNCancerDoc @oncology_bg @braintumourrsch"
X Link 2025-05-03T13:39Z [----] followers, 1M engagements
"$NWBO The Elephant in the Room: DCVax-L Merck and the Quiet Mobilization of a Global Immunotherapy Framework [---] Days of Silence and Still No Refusal DCVax-L the worlds most advanced autologous dendritic cell therapy for glioblastoma passed MHRA validation [---] days ago. Accounting for RFI pauses (60120 days) the regulatory review clock has far exceeded the 210-day norm with no Refusal to Grant (RTG) issued. No 8-K. No withdrawal. No red flags. This silence doesnt indicate rejectionit indicates complexity. Possibly coordination. Possibly scale. And yetMercks [----] Annual Shareholder Meeting"
X Link 2025-05-27T20:07Z [----] followers, [----] engagements
"$NWBO This slide from Biomedtracker (April 2025) confirms that: DCVax-Ls UK Approval Decision is officially expected between March [--] and June [--] [----]. 🔍 Key Insights: Label Listed: Brain Cancer (Malignant Glioma; AA and glioblastoma GBM) showing potential for both Grade III (Anaplastic Astrocytoma) and Grade IV (GBM) not just GBM alone. Placement Among High-Impact Therapies: DCVax-L is listed alongside gene therapies CAR-Ts and rare disease biologicsimplying Citeline sees it as a high-priority regulatory catalyst. Source Credibility: This is compiled by Citeline and shared through the"
X Link 2025-05-28T14:26Z [----] followers, [----] engagements
"The Question of All Questions: What Do [---] Billion Shares Actually Own in a Debt-Free $NWBO ⚖ Context Shift A company with [---] billion outstanding shares may seem bloated until the debt is fully cleared regulatory approval is imminent and that share base now owns: A validated personalized cancer vaccine A tissue-agnostic immunotherapy platform Fully built manufacturing infrastructure IP that can be franchised globally And the potential to treat tens of thousands of patients annually Lets walk through the numbers platform scope and strategic leverage that redefine NWBOs valuation math. 🔍 1."
X Link 2025-05-30T13:49Z [----] followers, 17.9K engagements
"$NWBO 🚀 The Tilt Heard Round the World: Flaskworks New Patent Rewrites the Playbook for Cell Therapy Automation (Expert-Level Analysis of WO2025/106534 A1 Published May [--] 2025) And yes📢 a shoutout again to Henry Mooney for delivering another infrastructure-defining upgrade behind the scenes. 🧬 What It Is WO2025/106534 is a new Flaskworks patent that introduces a precision mechanical system for automated GMP-compliant rotation tilt and agitation of bioreactors during the manufacturing of cellular therapies. This extends Flaskworks intellectual footprint beyond enclosed culture to include"
X Link 2025-06-05T17:15Z [----] followers, [----] engagements
"💣 $NWBO Legal Endgame Just Found Its Blueprint And Its Already Trading at a 22% Premium Quantum BioPharma (NASDAQ: QNTM) just detonated a playbook NWBO can follow and possibly exceed. On June [--] [----] QNTM announced a Contingent Value Rights (CVR) dividend tied to its ongoing spoofing lawsuit against CIBC and RBC. Each CVR grants shareholders 10%50% of any net recovery if litigation succeeds. The CVRs are: 1:1 per common share Non-transferable non-dilutive non-voting Cash-settled only if Quantum wins or settles Enforceable and unlinked from market price swings In [--] hours Quantum shares"
X Link 2025-06-17T16:47Z [----] followers, [----] engagements
"🔮 Why DCVax Cannot Be Skipped $NWBO And Why Adam Feuerstein Fears It Based on everything weve seen regulatory behavior public statements structural reforms and the groundwork already laid there is a compelling case that DCVax-L should receive MHRA approval before the final FDA CEO forum on July [--] [----]. This isnt speculation. Its what @adamfeuerstein has been trying to suppress and as @AndrewEcker829 brilliantly explains in The Silence Before the Snap its why so many biotech gatekeepers have gone quiet because the moment DCVax gets approved the old playbook breaks. 📎 The Silence Before the"
X Link 2025-06-19T11:45Z [----] followers, [----] engagements
"To Whom It May Concern Im not here to argue with trolls. Im here because this matters. $NWBO matters Im a board certified emergency and internal medicine physician. Ive worked countless night shifts helping people through their worst moments then spent my days building something of my own. That something is a wellness and weight loss clinic I opened under the Medi-Weightloss brand. Within a year I was asked to serve as Vice President of the Medi-Weightloss National Advisory Committee due to the consistently strong clinical outcomes at my clinic. While I no longer hold that role I remain an"
X Link 2025-07-08T06:11Z [----] followers, 10.5K engagements
"📘 $NWBO $MRK: The Textbook and the Teacher & How #DCVAX-L Quietly Rewrote the Rules of Cancer Vaccines 📢 TLDR: Most people think DCVAX L is a personalized tumor vaccine but that is not exactly true. The real genius is that it trains your immune system using a prebuilt tumor lysate library without needing a fresh tumor sample. The personalization comes not from the tumor but from the dendritic cells which must be your own. This design changes everything. It is scalable efficient and still fully individualized. 🧬 The Lysate is Shared For years people assumed the power of DCVAX came from"
X Link 2025-07-09T00:09Z [----] followers, [----] engagements
"🧠Strategic Convergence: Yorkville $NWBO Indaptus and Modular Immune Architecture 📡 TL;DR (22-25 min read): Yorkvilles dual financing of NWBO and $INDP reveals a deeper strategy: the rise of a programmable immunotherapy system. #DCVax DECOY20 and Eden form the core of an adaptive platform that integrates danger signals viral ignition and synthetic TLR boosters. Not a drug; a system. Not a company; a platform. In early [----] Yorkville Advisors (YA II PN Ltd.) executed two sequential financing agreements: [--]. A $5 million convertible note with Northwest Biotherapeutics announced on February 13"
X Link 2025-07-14T08:56Z [----] followers, [----] engagements
"X just shut down my ability to boost posts. I wonder why $NWBO"
X Link 2025-07-14T15:30Z [----] followers, [----] engagements
"🧬 This Is How You Launch an Immune Engine in [--] Months #DCVax CNPV and the Rise of the Modular Cancer Vaccine $NWBO $MRK $PFE $BMY The FDA didnt just open a new review pathway They created a fast pass for therapies that can change medicine Its called the Commissioners National Priority Voucher (CNPV) and if executed correctly it could deliver full FDA approval for DCVax-L in [--] months or less DCVax-Direct isnt far behind And the Mayo Clinic already proved the method Heres how it works Step One: The Voucher That Changed the Game No BLA required to apply No need to restart trials Just submit a"
X Link 2025-07-22T22:04Z [----] followers, [----] engagements
"🧭 The Scout the Silence and the System How $MRK Built What $BMY Walked Past and What $NWBO Had Already Finished In late [----] something unusual happened. Dr. Kevin Duffy Mercks Research Scientific Director on the Keytruda program quietly stepped away from one of the most dominant checkpoint franchises in oncology and joined a small quietly advancing company called Northwest Biotherapeutics. His time there was brief. He stayed just nine months. There was no announcement when he left. He returned to Merck with no new title no public acknowledgment and no external statement. But shortly after he"
X Link 2025-07-27T11:40Z [----] followers, [----] engagements
"🚀 Dr. Linda Liaus CNS Stage The Strategic Centerpiece for $NWBO and #DCVax-L On October [--] [----] Dr. Linda Liau will address the 75th Annual Congress of Neurological Surgeons (CNS) presenting Bench to Bedside: Evolution of Clinical Trials DCVax-L for Primary and Recurrent GBM. The CNS meeting is one of the most influential professional gatherings in the neurological field bringing together more than [-----] neurosurgeons neuro-oncologists and research leaders from over [--] countries. This audience is not composed of passive observers; they are the global operators of the neuro-oncology ecosystem"
X Link 2025-08-13T17:15Z [----] followers, 16.1K engagements
"🔬🕊 Les Goldmans Quiet Architecture: The Life and Work Behind $NWBO #DCVax 🌱 Part I. Foundations of a Builder Good evening. Tonight we look back on the life of a man who did not seek the headlines but who shaped the institutions behind them. Leslie J. Goldman was born in Chicago on April [--] [----]. His years would stretch from the end of the Second World War into the twenty-first centurys battle with cancer a span of history where the survival of institutions was often as fragile as the survival of the people they served. Goldman came of age at the University of Michigan. He graduated with a"
X Link 2025-08-18T22:05Z [----] followers, [----] engagements
"🧠 From N = [--] to the Long Tail: A Survivors Chronicle of #GBM and the $NWBO #DCVax-L Trial TLDR This interview with @ThomasOwenMcCa1 was done to personalize the DCVax-L story not just numbers but lived experience. Diagnosed with GBM where most survive [--] to [--] months and fewer than [--] percent reach five years Thomas is alive more than [--] years and [--] months later after surgery radiation chemo and DCVax-L. The JAMA Oncology Phase III trial confirmed DCVax-L extended survival in both newly diagnosed and recurrent patients with the five-year survival tail more than doubled and more than [----] doses"
X Link 2025-09-19T00:34Z [----] followers, 11.3K engagements
"The Disappearing Combo How a withdrawn trial at #UCLA revealed the quiet architecture connecting $BMS $MRK and $NWBO and the people who taught the immune system to remember Prologue The Vanished Trial The notice appeared without ceremony. A single line on described a new study at UCLAs Jonsson Comprehensive Cancer Center. Patients with lethal brain tumors would receive two of Bristol Myers Squibbs most famous checkpoint inhibitorsYervoy (ipilimumab) and Opdivo (nivolumab)alongside a dendritic-cell vaccine made from their own tumors. It was small careful and quietly revolutionary: acceleration"
X Link 2025-10-14T02:03Z [----] followers, [----] engagements
"🚨 $NWBO Math Check #AdventBioServices the only digital GMP facility in the UK would cost an estimated $700M+ to replicate. Yet $NWBO entire market cap is just $361M at $0.25/share (1.5B shares). That means the market values Advent + #Flaskworks + all #DCVax IP for less than half of Advent alone. And thats before MHRA approval partnerships or global expansion. Somethings off. #NWBO #DCVax #Biotech #MHRA #GMP #Immunotherapy #Glioblastoma #Investing #Stocks https://twitter.com/i/web/status/1982853215323291948 https://twitter.com/i/web/status/1982853215323291948"
X Link 2025-10-27T16:53Z [----] followers, [----] engagements
"🧬🔥 THE QUIET INFLECTION: How $NWBO Q3 [----] Filing Reveals a Company Moving From Development to Deployment A Global Forensic Deep-Read for Investors TLDR Northwest Biotherapeutics Q3 [----] Form 10-Q shows a company crossing a structural threshold. Without stating it outright the filing reveals a clean regulatory posture a secured manufacturing base through the full acquisition of Advent BioServices the buildout of new capacity through the Sawston C-lab the selection of a U.S. GMP node and a financial structure held together not by desperation but by lender confidence. There were no delays no"
X Link 2025-11-14T23:17Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing